

Untitled

? Help Off Line

* * *

Connecting to N. Archie - Dialog - 294084

Connected to Dialog via SMS00314899

? au=wooters, j?

>>>E: Unrecognizable command

? e au=wooters, j?

>>>E: No valid databases specified

? b biochem biosci biotech medicine

>>>W: 76 is unauthorized

44 is unauthorized

138 is unauthorized

3 of the specified files are not available

[File 5] Biosis Previews(R) 1926-2008/Jun w1

(c) 2008 The Thomson Corporation. All rights reserved.

[File 6] NTIS 1964-2008/Jun w2

(c) 2008 NTIS, Intl Cpyrght All Rights Res. All rights reserved.

[File 24] CSA Life Sciences Abstracts 1966-2008/Mar

(c) 2008 CSA. All rights reserved.

[File 34] SciSearch(R) Cited Ref Sci 1990-2008/Jun w2

(c) 2008 The Thomson Corp. All rights reserved.

[File 40] Enviroline(R) 1975-2008/Apr

(c) 2008 Congressional Information Service. All rights reserved.

[File 41] Pollution Abstracts 1966-2008/May

(c) 2008 CSA. All rights reserved.

[File 45] EMCare 2008/May w4

(c) 2008 Elsevier B.V. All rights reserved.

[File 50] CAB Abstracts 1972-2008/Apr

(c) 2008 CAB International. All rights reserved.

[File 65] Inside Conferences 1993-2008/Jun 06

(c) 2008 BLDSC all rts. reserv. All rights reserved.

[File 71] ELSEVIER BIOBASE 1994-2008/May w3

(c) 2008 Elsevier B.V. All rights reserved.

[File 73] EMBASE 1974-2008/Jun 05

(c) 2008 Elsevier B.V. All rights reserved.

*File 73: The 2008 Emtree Thesaurus has been loaded. Please see HELP NEWS 72 for details.

[File 98] General Sci Abs 1984-2008/May

(c) 2008 The HW Wilson Co. All rights reserved.

[File 103] Energy SciTec 1974-2008/Mar B1

(c) 2008 Contains copyrighted material. All rights reserved.

*File 103: For access restrictions see Help Restrict.

[File 136] BioEngineering Abstracts 1966-2007/Jan

(c) 2007 CSA. All rights reserved.

*File 136: This file is closed.

[File 143] Biol. & Agric. Index 1983-2008/Apr

(c) 2008 The HW Wilson Co. All rights reserved.

[File 144] Pascal 1973-2008/Jun w2

(c) 2008 INIST/CNRS. All rights reserved.

[File 155] MEDLINE(R) 1950-2008/Jun 09

(c) format only 2008 Dialog. All rights reserved.

*File 155: MEDLINE has reloaded. Please see HELP NEWS 155 for details.

[File 156] ToxFile 1965-2008/Jun w1

(c) format only 2008 Dialog. All rights reserved.

*File 156: ToxFile has been reloaded. Accession numbers have changed.

[File 162] Global Health 1983-2008/Apr

(c) 2008 CAB International. All rights reserved.

[File 172] EMBASE Alert 2008/Jun 06

Untitled

(c) 2008 Elsevier B.V. All rights reserved.
[File 305] Analytical Abstracts 1980-2008/Apr w3
(c) 2008 Royal Soc Chemistry. All rights reserved.
*File 305: Alert feature enhanced for multiple files, duplicate removal, customized scheduling. See HELP ALERT.
[File 369] New Scientist 1994-2008/Feb w4
(c) 2008 Reed Business Information Ltd. All rights reserved.
[File 370] Science 1996-1999/Jul w3
(c) 1999 AAS. All rights reserved.
*File 370: This file is closed (no updates). Use File 47 for more current information.
[File 393] Beilstein Database - Abstracts 2007/Q4
(c) 2008 Beilstein GmbH. All rights reserved.
[File 399] CA SEARCH(R) 1967-2008/UD=14824
(c) 2008 American Chemical Society. All rights reserved.
*File 399: Use is subject to the terms of your user/customer agreement. IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.
[File 434] SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 2006 The Thomson Corp. All rights reserved.
[File 28] Oceanic Abstracts 1966-2008/Jun
(c) 2008 CSA. All rights reserved.
[File 35] Dissertation Abs Online 1861-2008/Nov
(c) 2008 ProQuest Info&Learning. All rights reserved.
[File 91] MANTIS(TM) 1880-2008/Aug
2001 (c) Action Potential. All rights reserved.
[File 110] WasteInfo 1974-2002/Jul
(c) 2002 AEA Techn Env. All rights reserved.
*File 110: This file is closed (no updates)
[File 135] NewsRx Weekly Reports 1995-2008/Jun w1
(c) 2008 NewsRx. All rights reserved.
[File 164] Allied & Complementary Medicine 1984-2008/Jun
(c) 2008 BLHCIS. All rights reserved.
[File 185] Zoological Record Online(R) 1864-2008/Jun
(c) 2008 The Thomson Corp. All rights reserved.
*File 185: The file has been reloaded to add archive records back to 1864. Accession numbers have changed.
[File 357] Derwent Biotech Res. 1982-2008/May w2
(c) 2008 The Thomson Corp. All rights reserved.
[File 391] Beilstein Database - Reactions 2007/Q4
(c) 2008 Beilstein GmbH. All rights reserved.
[File 467] ExtraMED(tm) 2000/Dec
(c) 2001 Informania Ltd. All rights reserved.
[File 8] Ei Compindex(R) 1884-2008/May w3
(c) 2008 Elsevier Eng. Info. Inc. All rights reserved.
[File 99] Wilson Appl. Sci & Tech Abs 1983-2008/Apr
(c) 2008 The HW Wilson Co. All rights reserved.
[File 266] FEDRIP 2008/Feb
Comp & dist by NTIS, Intl Copyright All Rights Res. All rights reserved.
[File 315] ChemEng & Biotech Abs 1970-2008/May
(c) 2008 DECHEMA. All rights reserved.
*File 315: December 2007 - the reloaded database is now online. Please consult the updated bluesheet for details on new and changed fields.
[File 358] Current BioTech Abs 1983-2006/Jan
(c) 2006 DECHEMA. All rights reserved.
*File 358: This file is no longer updating. Please use File 315, which includes all File 358 records and updates.
[File 149] TGG Health&Wellness DB(SM) 1976-2008/May w4
(c) 2008 The Gale Group. All rights reserved.
[File 159] Cancerlit 1975-2002/Oct
(c) format only 2002 Dialog. All rights reserved.
[File 444] New England Journal of Med. 1985-2008/Mar w3
(c) 2008 Mass. Med. Soc. All rights reserved.

Untitled

? e au=wooters, joseph?

| Ref | Items | Index-term |
|-----|-------|-----------------------------|
| E1 | 1 | AU=WOOTERS, JOSEPH LAWRENCE |
| E2 | 1 | AU=WOOTERS, JOSEPH M. |
| E3 | 0 | AU=WOOTERS, JOSEPH? |
| E4 | 2 | AU=WOOTERS, JUDSON |
| E5 | 2 | AU=WOOTERS, K. |
| E6 | 2 | AU=WOOTERS, MELISSA |
| E7 | 1 | AU=WOOTERS, MELISSA A. |
| E8 | 3 | AU=WOOTERS, MELISSA A. |
| E9 | 2 | AU=WOOTERS, S. C. |
| E10 | 1 | AU=WOOTERS, S. CRAIG |
| E11 | 1 | AU=WOOTERS, T. E |
| E12 | 1 | AU=WOOTERS, T. E. |
| E13 | 1 | AU=WOOTERS, T. JUDSON |
| E14 | 1 | AU=WOOTERS, THOMAS E. |
| E15 | 1 | AU=WOOTERS, CHUCK |
| E16 | 1 | AU=WOOTFENDEN, G. E. |
| E17 | 1 | AU=WOOTFSON DEREK N |
| E18 | 1 | AU=WOOTFSON DN |
| E19 | 1 | AU=WOOTHERSPOON J T M |
| E20 | 1 | AU=WOOTHIPPOOM |
| E21 | 8 | AU=WOOTHIPPOOM W |
| E22 | 4 | AU=WOOTHIPPOOM W. |
| E23 | 2 | AU=WOOTHIPPOOM, W. |
| E24 | 1 | AU=WOOTI S |
| E25 | 1 | AU=WOOTIEN A |

Enter PAGE for more

? e au=metcalf, benjamin?

| Ref | Items | Index-term |
|-----|-------|---------------------------|
| E1 | 2 | AU=METCALF, BENJAMIN J |
| E2 | 11 | AU=METCALF, BENJAMIN J. |
| E3 | 0 | AU=METCALF, BENJAMIN? |
| E4 | 1 | AU=METCALF, BETTYE HARRIS |
| E5 | 5 | AU=METCALF, BJ |
| E6 | 1 | AU=METCALF, BM |
| E7 | 1 | AU=METCALF, BOB |
| E8 | 1 | AU=METCALF, BONNIE G. |
| E9 | 1 | AU=METCALF, BR |
| E10 | 4 | AU=METCALF, BRAD |
| E11 | 4 | AU=METCALF, BRAD S |
| E12 | 7 | AU=METCALF, BRAD S. |
| E13 | 1 | AU=METCALF, BRADLEY S |
| E14 | 5 | AU=METCALF, BRADLEY S. |
| E15 | 1 | AU=METCALF, BRETT T. |
| E16 | 80 | AU=METCALF, BRIAN |
| E17 | 1 | AU=METCALF, BRIAN L. |
| E18 | 1 | AU=METCALF, BRIAN ROUNDS |
| E19 | 4 | AU=METCALF, BRIAN W |
| E20 | 9 | AU=METCALF, BRIAN W (ED) |
| E21 | 362 | AU=METCALF, BRIAN W. |
| E22 | 15 | AU=METCALF, BRIAN W. (ED) |
| E23 | 33 | AU=METCALF, BRIAN WALTER |
| E24 | 1 | AU=METCALF, BRUCE |
| E25 | 5 | AU=METCALF, BRUCE D. |

Enter PAGE for more

? s e1-e2

| | |
|----|-------------------------|
| 2 | AU=METCALF, BENJAMIN J |
| 11 | AU=METCALF, BENJAMIN J. |

S1 13 S E1-E2

? s s1 and chlamydia

13 S1
128570 CHLAMYDIA
S2 1 S S1 AND CHLAMYDIA

? e au=sankaran, banumathi?

| Ref | Items | Index-term |
|-----|-------|------------------------------------|
| E1 | 6 | AU=SANKARAN, BALU |
| E2 | 21 | AU=SANKARAN, BANUMATHI |
| E3 | 0 | AU=SANKARAN, BANUMATHI? |
| E4 | 1 | AU=SANKARAN, BASKARAN |
| E5 | 6 | AU=SANKARAN, C |
| E6 | 25 | AU=SANKARAN, C. |
| E7 | 1 | AU=SANKARAN, CHANDINI |
| E8 | 2 | AU=SANKARAN, CHANDRAMOULISVARA |
| E9 | 7 | AU=SANKARAN, CHANDRASEKAR |
| E10 | 2 | AU=SANKARAN, CHANDY |
| E11 | 5 | AU=SANKARAN, D |
| E12 | 17 | AU=SANKARAN, D. |
| E13 | 1 | AU=SANKARAN, D. P. |
| E14 | 6 | AU=SANKARAN, DAVID |
| E15 | 12 | AU=SANKARAN, DEEPA |
| E16 | 1 | AU=SANKARAN, DESAMANGALAM KRISHNAN |
| E17 | 1 | AU=SANKARAN, E |
| E18 | 1 | AU=SANKARAN, E. |
| E19 | 1 | AU=SANKARAN, G |
| E20 | 12 | AU=SANKARAN, G. |
| E21 | 2 | AU=SANKARAN, G. K. |
| E22 | 4 | AU=SANKARAN, G. V. |
| E23 | 1 | AU=SANKARAN, G.K. |
| E24 | 2 | AU=SANKARAN, GOPAL |
| E25 | 22 | AU=SANKARAN, H |

Enter PAGE for more

? s e2 and chlamydia

21 AU=SANKARAN, BANUMATHI
128570 CHLAMYDIA
S3 1 AU='SANKARAN, BANUMATHI' AND CHLAMYDIA

? s chlamydia or chlamydiae

128570 CHLAMYDIA
7269 CHLAMYDIAE
S4 129950 S CHLAMYDIA OR CHLAMYDIAE

? S 4 and (cyclophilin or cyclophilin A or Cypa)

Processing
Processing
Processing
28405096 4
18213 CYCLOPHILIN
1501 CYCLOPHILIN A
1697 CYPA
S5 3642 S 4 AND (CYCLOPHILIN OR CYCLOPHILIN A OR CYPA)

? s s5 and (treat\$ or administ\$ or challenge or vaccine or intra\$ or immuniz\$ or antibod\$ or immunoglobul\$)

3642 S5
0 TREAT\$
0 ADMINIST\$
929011 CHALLENGE
844949 VACCINE

Untitled

```

0   INTRAS$
0   IMMUNIZ$
0   ANTIBOD$
0   IMMUNOGLOBUL$
S6   120   S 55 AND (TREAT$ OR ADMINIST$ OR CHALLENGE OR VACCINE OR INTRAS$ OR
IMMUNIZ$ OR ANTIBOD$ OR IMMUNOGLOBUL$)

```

? rd

>>>W: Duplicate detection is not supported for File 393.
Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S7 83 RD (UNIQUE ITEMS)

? t s7/3,k/1-83

>>>W: KWIC option is not available in file(s): 399
7/3,k/1 (Item 1 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.
0019902731 Biosis No.: 200700562472

The three-dimensional structure of two redox states of cyclophilin A from
Schistosoma mansoni - Evidence for redox regulation of peptidyl-prolyl cis-trans
isomerase activity

Author: Gourlay Louise J; Angelucci Francesco; Baiocco Paola; Boumis Giovanna;
Brunori Maurizio; Bellelli Andrea (Reprint); Miele Adriana E
Author Address: Univ Roma La Sapienza, Dept Biochim, P le A Moro 5, I-00185 Rome,
Italy** Italy

Author E-mail Address: andrea.bellelli@uniroma1.it
Journal: Journal of Biological Chemistry 282 (34): p 24851-24857 AUG 24 2007
2007

ISSN: 0021-9258

Document Type: Article

Record Type: Abstract

Language: English

The three-dimensional structure of two redox states of cyclophilin A from
Schistosoma mansoni - Evidence for redox regulation of peptidyl-prolyl cis-trans
isomerase activity

Abstract: ...mice infected with Schistosoma mansoni. Given the well established
interaction between cyclosporin A and the cyclophilin superfamily of peptidylprolyl
cis-trans isomerases, we solved the structure of cyclophilin A from S. mansoni
(SmCypA) by x-ray crystallography in the reduced and oxidized states...
...C-terminal cysteines (Cys-122 and Cys-126). This is the first example of a
cyclophilin containing this disulfide bridge. Parallel functional studies suggest a
mechanism for regulation of SmCypA activity... ..7) M-1 s(-1), and it is inhibited
by cyclosporin A (IC50 of 14 +/- 4 nM). The lack of conservation of this cysteine
couple within the CypA superfamily, their close proximity to the active site, and
the importance of thiol groups for peptidyl-prolyl cis-trans isomerase activity
render this structural feature a challenge for the development of alternative and
more effective anti-schistosomiasis inhibitors and may in addition...

DESCRIPTORS:

Chemicals & Biochemicals: ...cyclophilin A

7/3,k/2 (Item 2 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.
19232494 Biosis No.: 200600577889

Novel approach to inhibit asthma-mediated lung inflammation using anti-CD147
intervention

Untitled

Author: Gwinn William M; Damsker Jesse M; Falahati Rustom; Okwumabua Ifeanyi;
Kelly-welch Ann; Keegan Achsah D; Vanpouille Christophe; Lee James J; Dent Lindsay
A; Leitenberg David; Bukrinsky Michael I; Constant Stephanie L (Reprint)
Author Address: George Washington Univ, Med Ctr, Dept Microbiol Immunol and Trop
Med, Ross Hall 738,2300 Eye St NW, Washington, DC 20037 USA**USA
Author E-mail Address: mtmslc@gwumc.edu
Journal: Journal of Immunology 177 (7) : p 4870-4879 OCT 1 2006 2006
ISSN: 0022-1767
Document Type: Article
Record Type: Abstract
Language: English

Abstract: ...from the periphery into tissues during inflammatory responses. In this study, we examined whether extracellular cyclophilin-CD147 interactions might influence leukocyte recruitment in the inflammatory disease allergic asthma. Using a mouse... ..upon activation; 3) cyclophilins induce CD147-dependent chemotaxis of activated CD4(+) T cells in vitro; 4) in vivo treatment with anti-CD147 mAb significantly reduces (by up to 50%) the accumulation... ..5) anti-CD147 treatment significantly reduces airway epithelial mucin production and bronchial hyperreactivity to metacholine challenge. These findings provide a novel mechanism whereby asthmatic lung inflammation may be reduced by targeting cyclophilin-CD147 interactions.

DESCRIPTORS:

Chemicals & Biochemicals: ...cyclophilin;

Miscellaneous Terms: Concept Codes: ...cyclophilin-CD147

7/3,K/3 (Item 3 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

14992788 Biosis No.: 199900252448

Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines

Author: Jarvelainen Harri A; Fang Che; Ingelman-Sundberg Magnus; Lindros Kai O (Reprint)

Author Address: Alcohol Research Center, National Public Health Institute, 00101, Helsinki, Finland**Finland

Journal: Hepatology 29 (5) : p 1503-1510 May, 1999 1999

Medium: print

ISSN: 0270-9139

Document Type: Article

Record Type: Abstract

Language: English

Abstract: ...ethanol-containing liquid diet, some rats also were infused with endotoxin via osmotic minipumps for 4 additional weeks. Ethanol diet alone increased plasma endotoxin threefold to 9.3 pg/mL. Endotoxin... ..tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta) and anti-inflammatory cytokines IL-4 and IL-10 were markedly increased, as shown by competitive polymerase chain reaction (PCR) analysis using cyclophilin as standard. The effect of endotoxin infusion on cytokine mRNA expression in ethanol-fed animals... ..significantly increased by chronic endotoxin treatment, contrasting with the marked elevation observed after acute endotoxin challenge. These results suggest that the tolerance observed despite sustained hepatic expression of proinflammatory cytokines is...

7/3,K/4 (Item 4 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

Page 6

Untitled

13523729 Biosis No.: 199699157789

Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formyl-methionyl-leucyl-phenylalanine

Author: De Paulis Amato; Ciccarelli Anna; De Crescenzo Gennaro; Cirillo Raffaele; Patella Vincenzo; Marone Gianni (Reprint)
Author Address: Div. Clin. Immunol. Allergy, Univ. Naples Federico II, Sch. Med., Via S. Pansini 5, 80131 Napoli, Italy**Italy
Journal: Journal of Allergy and Clinical Immunology 98 (1): p 152-164 1996 1996
ISSN: 0091-6749
Document Type: Article
Record Type: Abstract
Language: English

Abstract: Background: Cyclosporin A (CsA) binds with high affinity to cyclophilin, a critical step in the molecular mechanism of action of cyclosporins, whereas cyclosporin H (CsH) has extremely low affinity for cyclophilin. CsH differs from CsA by the substitution of the L-methyl valine at position 11... ..on the release of preformed (histamine) and de novo synthesized inflammatory mediators (peptide leukotriene C-4) from peripheral blood basophils activated by N-formyl-methionyl-leucyl-phenylalanine (FMLP). Results: CsH (8 to 800 nmol/L) concentration-dependently inhibited histamine and leukotriene C-4 release from purified and unpurified basophils activated by FMLP, whereas CsA (8 to 800 nmol... ..with FMLP was extremely rapid and was abolished by washing the cells (three times) before challenge. CsH (8 to 800 nmol/L) had no effect on the release of histamine caused... ..human polymorphonuclear leukocytes with a concentration required to inhibit binding by 50% of approximately 5.4×10^{-7} mol/L, whereas BoCMLP was less potent with a concentration required to... ..

Registry Numbers: ...LEUKOTRIENE C-4;

Enzyme Commission Number:

DESCRIPTORS:

Chemicals & Biochemicals: ...LEUKOTRIENE C-4;

Miscellaneous Terms: Concept Codes: ...LEUKOTRIENE C-4

7/3,K/5 (Item 5 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

11330286 Biosis No.: 199294032127

ANTI-INFLAMMATORY EFFECT OF CYCLOSPORIN A ON HUMAN SKIN MAST CELLS

Author: STELLATO C (Reprint); DE PAULIS A; CICCARELLI A; CIRILLO R; PATELLA V; CASOLARO V; MARONE G
Author Address: CATTEDRA DI IMMUNOLOGIA CLINICA ALLERGOLOGIA, II FACOLTA DI MEDICINA CHIRURGIA, UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II, VIA SERGIO PANSINI 5, 80131 NAPOLI, ITALY**ITALY
Journal: Journal of Investigative Dermatology 98 (5): p 800-804 1992
ISSN: 0022-202X
Document Type: Article
Record Type: Abstract
Language: ENGLISH

Abstract: ...effects of cyclosporin A (CsA) and cyclosporin H (CsH), which bind with different affinity to cyclophilin, to evaluate the role of this protein in the release of preformed (histamine) and de... ..prostaglandin D2[PGD2]) mediators of inflammatory reactions from human skin mast cells (HSMC). CsA (2.4-800 nM)-inhibited (5-60%) histamine release from HSMC challenged with anti-IgE. CsA exerted... ..extremely rapid and was not abolished by washing (three times) the cells before anti-IgE challenge. CsA (2.4-800 nM) markedly inhibited (25-70%) the de novo synthesis of PGD2 from HSMC challenged with anti-IgE. CsH, which has an extremely low affinity for cyclophilin, had no effect on skin mast-cell mediator release. These data suggest that CsA is a potent anti-inflammatory agent acting on HSMC,

Untitled
presumably by interacting with cyclophilin.

7/3,K/6 (Item 6 from file: 5) Links
Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rights reserved.
10259075 Biosis No.: 199090043554
CYCLOSPORIN A RAPIDLY INHIBITS MEDIATOR RELEASE FROM HUMAN BASOPHILS PRESUMABLY BY INTERACTING WITH CYCLOPHILIN

Author: CIRILLO R (Reprint); TRIGGIANI M; SIRI L; CICCARELLI A; PETTIT G R;
CONDORELLI M; MARONE G
Author Address: DIV DI IMMUNOL CLIN, II FAC DI MED, VIA S PANSINI 5, 80131 NAPOLI,
ITALY** ITALY
Journal: Journal of Immunology 144 (10): p 3891-3897 1990
ISSN: 0022-1767
Document Type: Article
Record Type: Abstract
Language: ENGLISH
CYCLOSPORIN A RAPIDLY INHIBITS MEDIATOR RELEASE FROM HUMAN BASOPHILS PRESUMABLY BY INTERACTING WITH CYCLOPHILIN

Abstract: ...cyclosporin A (CsA) and a series of CsA analogs that bind with decreasing affinity to cyclophilin, to evaluate the involvement of this protein in the release of preformed (histamine) and de... ...challenged with anti-IgE. CsA was more potent (92.6 +/- 1.8 vs 59.1 +/- 4.5%; p < 0.001) and, at low concentrations, more effective when the channel-operated influx... ...with anti-IgE was not abolished by washing (three times) the cells before anti-IgE challenge. CsA also inhibited the de novo synthesis of LTC4 from basophils challenged with anti-IgE... ...CsG, CsC, CsD, and CsH) showed that CsH, which has an extremely low affinity for cyclophilin, has no effect on basophil mediator release. In addition, there is a significant correlation between... ...0.001) and by A23187 (r = 0.87; p < 0.001) and their affinity for cyclophilin.

7/3,K/7 (Item 1 from file: 34) Links
Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2008 The Thomson Corp. All rights reserved.
05408279 Genuine Article#: VX026 No. References: 37
INDUCTION OF ANERGY IN CD8 T-CELLS BY B-CELL PRESENTATION OF ANTIGEN

Author: HOLLSBERG P; BATRA V; DRESSSEL A; HAFER DA
Corporate Source: BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,LAB MOL IMMUNOL,LMRC-113,221 LONGWOOD AVE/BOSTON//MA/02115; HARVARD UNIV,SCH MED/BOSTON//MA/02115
Journal: JOURNAL OF IMMUNOLOGY , 1996 , V 157 , N12 (DEC 15) , P 5269-5276
ISSN: 0022-1767
Language: ENGLISH Document Type: ARTICLE (Abstract Available)
Abstract: ...B cells, or T cells was sufficient to induce complete unresponsiveness to a secondary Ag challenge. This was not caused by lack of B7 costimulation since the APCs expressed B7-1...
Identifiers-- ...CLONAL ANERGY; INTERLEUKIN-2 PRODUCTION; RECEPTOR OCCUPANCY; LYMPHOCYTES-T; ACTIVATION; CTLA-4; COSTIMULATION; TOLERANCE; PROLIFERATION; PATHWAY Research Fronts: ...COSTIMULATORY MOLECULE; ACTIVATED MURINE B-LYMPHOCYTES; FUNCTIONAL EXPRESSION; TRANSGENIC MICE; CD28 CO-STIMULATION; SOLUBLE CTLA-4) 94-2560 001 (RAPAMYCIN IN T-LYMPHOCYTES; INHIBITION OF CALCINEURIN; IMMUNOSUPPRESSIVE AGENTS; MACROLIDE FK506; CYCLOPHILIN CYCLOSPORINE-A COMPLEX)
Cited References:

Untitled

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

05314449 Genuine Article#: VP585 No. References: 56

ADENOVIRUS-ENHANCED RECEPTOR-MEDIATED TRANSFERRIN INFECTION FOR THE GENERATION OF TUMOR VACCINES

Author: SCHWEIGHOFFER T; BERGER M; BUSCHLE M; SCHMIDT W; BIRNSTIEL ML
Corporate Source: RES INST MOL PATHOL, DR BOHR GASSE 7/A-1030 VIENNA//AUSTRIA/
Journal: CYTOKINES AND MOLECULAR THERAPY, 1996, V 2, N3 (SEP), P 185-191
ISSN: 1355-6568

Language: ENGLISH Document Type: ARTICLE (Abstract Available)

Abstract: ...vaccinations with transfected cells secreting IL-2 protect animals from tumor development by a subsequent challenge, and result in long-lasting tumor-specific immunity dependent on both CD4(+) and CD8(+) T ...

Identifiers--

Research Fronts: ...COSTIMULATORY MOLECULE; ACTIVATED MURINE B-LYMPHOCYTES; FUNCTIONAL EXPRESSION; TRANSGENIC MICE; CD28 CO-STIMULATION; SOLUBLE CTLA-4)
94-0428 002 (MEMORY CD4(+)) T-CELL ADHESION; MULTIPLE SUBSETS; DIFFERENTIAL EXPRESSION; CD45RA(+) PERIPHERAL-BLOOD... LYMPHOCYTES)

94-2560 001 (RAPAMYCIN IN T-LYMPHOCYTES; INHIBITION OF CALCINEURIN; IMMUNOSUPPRESSIVE AGENTS; MACROLIDE FK506; CYCLOPHILIN CYCLOSPORINE-A COMPLEX)
94-4053 001 (LIVER-DIRECTED GENE DELIVERY; RECEPTOR-MEDIATED ENDOCYTOSIS; HEPATOCYTES IN...

Cited References:

7/3,K/9 (Item 3 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

05189393 Genuine Article#: VG030 No. References: 111

CHAPERONE AND FOLDASE COEXPRESSION IN THE BACULOVIRUS-INSECT CELL EXPRESSION SYSTEM

Author: BETENBAUGH MJ; AILOR E; WHITELEY E; HINDERLITER P; HSU TA
Corporate Source: JOHNS HOPKINS UNIV, DEPT CHEM ENGN, 028 NEW ENGL
BLDG/BALTIMORE//MD/21218

Journal: CYTOTECNOLOGY, 1996, V 20, N1-3, P 149-159
ISSN: 0920-9069

Language: ENGLISH Document Type: REVIEW

Identifiers-- ...PROTEIN DISULFIDE-ISOMERASE; CIS-TRANS-ISOMERASE; CHAIN BINDING-PROTEIN; TISSUE-PLASMINOGEN-ACTIVATOR; HUMAN PROLYL 4-HYDROXYLASE; CYCLOPHILIN HOMOLOG NINAA; HUMAN INSULIN-RECEPTOR; HAMSTER OVARY CELLS; FOLDING IN-VITRO; ENDOPLASMIC-RETICULUM

Research Fronts: ...GENE)

94-2560 003 (RAPAMYCIN IN T-LYMPHOCYTES; INHIBITION OF CALCINEURIN; IMMUNOSUPPRESSIVE AGENTS; MACROLIDE FK506; CYCLOPHILIN CYCLOSPORINE-A COMPLEX)
94-1653 001 (SYNAPTIC VESICLE PROTEINS; REGULATED EXOCYTOSIS; NONPOLARIZED CELLS)
94-2758 001 (BACULOVIRUS EXPRESSION SYSTEM; AUTOGRAPH-A-CALIFORNICA NUCLEAR

POLYHEDROSIS-VIRUS; INSECT CELLS; RECOMBINANT VACCINE FOR MINK ENTERITIS PARVOVIRUS)
94-5622 001 (PROTEIN DISULFIDE-ISOMERASE; ASSEMBLY PATHWAY OF THE BACULOVIRUS...

7/3,K/10 (Item 4 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

05053030 Genuine Article#: TM387 No. References: 46

INDUCTION AND PREVENTION OF SHOCK-LIKE LETHAL SIDE-EFFECTS AFTER MICROFILARICIDAL TREATMENT IN FILARIAE INFECTED RODENTS

Author: ZAHNER H

Corporate Source: UNIV GIESSEN, INST PARASITOL, RUDOLF BUCHHEIM STR2/D-35392

Page 9

Untitled

GIESSEN//GERMANY/
Journal: TROPICAL MEDICINE AND PARASITOLOGY , 1995 , V 46 , N4 (DEC) , P 221-229
ISSN: 0177-2392
Language: ENGLISH Document Type: ARTICLE (Abstract Available)
Abstract: ...diethylcarbamazine, ivermectin, CGP 20376) and the parasite species, D-Gal-primed infected animals died within 4 days after a microfilaricidal treatment. Lethal effects did also occur in naive animals to which microfilariae had been transfused 18 h prior to the challenge with D-Gal and a microfilaricidal, provided the animals had received at least approximately 10...
Identifiers--
Research Fronts: ...GVHD)
94-2560 001 (RAPAMYCIN IN T-LYMPHOCYTES; INHIBITION OF CALCINEURIN;
IMMUNOSUPPRESSIVE AGENTS; MACROLIDE FK506; CYCLOPHILIN CYCLOSPORINE-A COMPLEX)
94-4880 001 (NITRIC-OXIDE SYNTHASE; RAT PERITONEAL MACROPHAGE CULTURES;
IRON-DERIVED...
Cited References:

7/3,K/11 (Item 5 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2008 The Thomson Corp. All rights reserved.
05050037 Genuine Article#: TL721 No. References: 63
INTERLEUKIN-2 DOWN-MODULATES MEMORY T-HELPER LYMPHOCYTE DEVELOPMENT DURING
ANTIGENIC-STIMULATION IN-VITRO

Author: BEMER V; MOTTA I; PERRET R; TRUFFABACHI P
Corporate Source: INST PASTEUR,UNITE IMMUNOPHYSIOL MOLEC/F-75724 PARIS 15//FRANCE/;
INST PASTEUR,UNITE IMMUNOPHYSIOL MOLEC/F-75724 PARIS 15//FRANCE/
Journal: EUROPEAN JOURNAL OF IMMUNOLOGY , 1995 , V 25 , N12 (DEC) , P 3394-3401
ISSN: 0014-2980
Language: ENGLISH Document Type: ARTICLE (Abstract Available)
Abstract: ...was revealed by their capacity to help virgin B splenocytes produce anti-SRBC antibodies upon challenge in vitro. We found that CD4(+) cells primed in the absence of IL-2, provoked... phenotype. The pattern of expression of the genes encoding different cytokines (IL-2, IL-4, IL-5 and interferon-gamma) following a secondary antigenic stimulation shows that the helper function...
Identifiers--
Research Fronts: ...RECEPTORS)
94-2560 001 (RAPAMYCIN IN T-LYMPHOCYTES; INHIBITION OF CALCINEURIN;
IMMUNOSUPPRESSIVE AGENTS; MACROLIDE FK506; CYCLOPHILIN CYCLOSPORINE-A COMPLEX)
94-3843 001 (LETHAL MURINE GRAFT-VERSUS-HOST DISEASE; GAMMA-DELTA T...
Cited References:

7/3,K/12 (Item 6 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2008 The Thomson Corp. All rights reserved.
04874363 Genuine Article#: UN889 No. References: 133
NOVEL COSTIMULATORS IN THE IMMUNE GENE-THERAPY OF CANCER

Author: GALEALAURO J; FARZANEH F; GAKEN J
Corporate Source: UNIV LONDON KINGS COLL,SCH MED & DENT,RAYNE INST,DEPT MOLEC MED,IMMUNE GENE THERAPY GRP/LONDON SE5 9NU//ENGLAND/; UNIV LONDON KINGS COLL,SCH MED & DENT,RAYNE INST,DEPT MOLEC MED,IMMUNE GENE THERAPY GRP/LONDON SE5 9NU//ENGLAND/
Journal: CANCER GENE THERAPY , 1996 , V 3 , N3 (MAY-JUN) , P 202-214
ISSN: 0929-1903
Language: ENGLISH Document Type: REVIEW (Abstract Available)
Abstract: ...their activation, and how such knowledge can be used to persuade the immune system to challenge cancer.
Identifiers--
Research Fronts: ...COSTIMULATORY MOLECULE; ACTIVATED MURINE B-LYMPHOCYTES;
Page 10

Untitled

FUNCTIONAL EXPRESSION; TRANSGENIC MICE; CD28 CO-STIMULATION; SOLUBLE CTLA-4)
94-0872 002 (T-CELL ANTIGEN RECEPTOR SIGNALING; TYROSINE KINASES; ACTIVATION OF
P56(LCK); SEQUENTIAL...MELANOMA)
94-2560 002 (RAPAMYCIN IN T-LYMPHOCYTES; INHIBITION OF CALCINEURIN;
IMMUNOSUPPRESSIVE AGENTS; MACROLIDE FK506; CYCLOPHILIN CYCLOSPORINE-A COMPLEX)
94-0149 001 (T-CELL RECEPTOR TRANSGENIC THYMOCYTES; SUPERANTIGEN STAPHYLOCOCCUS
ENTEROTOXIN-B ...
Cited References:

7/3,K/13 (Item 7 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2008 The Thomson Corp. All rights reserved.
04866971 Genuine Article#: UP080 No. References: 437
ENVELOPE GLYCOPROTEINS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 - PROFOUND INFLUENCES
ON IMMUNE FUNCTIONS

Author: CHIRMULE N; PAHWA S
Corporate Source: N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT
PEDIAT/MANHASSET/NY/11030
Journal: MICROBIOLOGICAL REVIEWS , 1996 , V 60 , N2 (JUN) , P 386&
ISSN: 0146-0749
Language: ENGLISH Document Type: REVIEW (Abstract Available)
Research Fronts: ...COSTIMULATORY MOLECULE; ACTIVATED MURINE B-LYMPHOCYTES;
FUNCTIONAL EXPRESSION; TRANSGENIC MICE; CD28 CO-STIMULATION; SOLUBLE CTLA-4)
94-1327 002 (BCL-2 PROTEIN EXPRESSION; REGULATION OF APOPTOSIS; PROGRAMMED
CELL-DEATH; TRANSGENIC MICE...SEPSIS)
94-2560 001 (RAPAMYCIN IN T-LYMPHOCYTES; INHIBITION OF CALCINEURIN;
IMMUNOSUPPRESSIVE AGENTS; MACROLIDE FK506; CYCLOPHILIN CYCLOSPORINE-A COMPLEX)
94-4380 001 (CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX MUTANT MICE; CYTOTOXIC T...
...SEQUENCE HOMOLOGY)
94-6414 001 (HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1; HIV PROTEASE INHIBITORS; GLOBAL
AIDS VACCINE; ANTIVIRAL ACTIVITY; NUCLEOSIDE ANALOGS)
Cited References:

7/3,K/14 (Item 8 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2008 The Thomson Corp. All rights reserved.
04834680 Genuine Article#: UK999 No. References: 52
CORTICOSTATINS/DEFENSINS INHIBIT IN-VITRO NK ACTIVITY AND CYTOKINE PRODUCTION BY
HUMAN PERIPHERAL-BLOOD MONONUCLEAR-CELLS

Author: MASERA RG; BATEMAN A; MUSCETTOLA M; SOLOMON S; ANGELI A
Corporate Source: UNIV TURIN,DIPARTIMENTO SCI CLIN & BIOL,CLIN MED
GEN/TURIN//ITALY; MCGILL UNIV,ROYAL VICTORIA HOSP,ENDOCRINE
LAB/MONTREAL/PQ/CANADA//; UNIV SIENA,IST FISOL GEN & SCI ALIMENTAZ/SIENA//ITALY/
Journal: REGULATORY PEPTIDES , 1996 , V 62 , N1 (APR 9) , P 13-21
ISSN: 0167-0115
Language: ENGLISH Document Type: ARTICLE (Abstract Available)
Abstract: ...adrenal axis. We wished to determine whether two human
corticostatsins/defensins, HP-1 and HP-4, are able to change in vitro the spontaneous
NK activity of human peripheral blood mononuclear... IL-2) and to the inhibitory
hormone cortisol, NK cell activity was measured in a 4-h direct cytotoxicity assay
with K562 cells as a target. HP-1 and HP-4 (10(-8)-10(-9) M) significantly inhibited
the spontaneous and cytokine-inducible NK activity, and... the two cell
preparations examined. We also evaluated the effects of HP-1 and HP-4 (10(-8)
M-10(-9) M) upon IFN-gamma and interleukin 6 (IL-6) production... the biological
assay using WISH cells as indicators and vesicular stomatitis virus (VSV) as the
challenge virus. IL-6 was measured using an enzyme amplified sensitivity
immunoassay, Both HP-1 and HP- 4 significantly reduced cytokine production. Our data

Untitled

indicate that corticostatin/defensins are novel modulators of lymphocyte...

Identifiers-

Research Fronts: ...EXPRESSION

94-2560 001 (RAPAMYCIN IN T-LYMPHOCYTES; INHIBITION OF CALCINEURIN;
IMMUNOSUPPRESSIVE AGENTS; MACROLIDE FK506; CYCLOPHILIN CYCLOSPORINE-A COMPLEX)

94-3876 001 (HUMAN NATURAL-KILLER-CELL RECEPTOR FOR MAJOR HISTOCOMPATIBILITY
COMPLEX...

Cited References:

7/3,K/15 (Item 1 from file: 45) Links

Fulltext available through: STIC Full Text Retrieval Options

EMCare

(c) 2008 Elsevier B.V. All rights reserved.

00812190 EMCare No: 30720176

Dichotomy between neurokinin receptor actions in modulating allergic airway
responses in an animal model of helper T cell type 2 cytokine-associated
inflammation

Maghni K.; Taha R.; Afif W.; Hamid Q.; Martin J.G.

J.G. Martin, Meakins-Christie Laboratories, McGill University, 3626 St. Urbain
Street, Montreal, Que. H2X 2P2 Canada

AUTHOR EMAIL: jmartin@meakins.lan.mcgill.ca

American Journal of Respiratory and Critical Care Medicine (AM. J. RESPIR. CRIT.

CARE MED.) (United States) 2000 , 162/3 I (1068-1074)

CODEN: AJCME ISSN: 1073-449X

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 52

RECORD TYPE: Abstract

Copyright 2006 Elsevier B.V., All rights reserved.

...are expressed in the lungs, and that SP is released in the airways after
allergen challenge. The selective NK-1 (CP-99,994) or NK-2 (SR-48968) antagonists
before allergen challenge failed to reduce the allergic early airway responses. In
contrast, both neurokinin antagonists decreased allergen... NK-2, but not NK-1,
antagonist decreased both Th1 (INF-gamma) and Th2 (IL-4 and -5) cytokine expression
in BAL cells by in situ hybridization. These results provide initial...

DESCRIPTORS:

*
receptor; allergen; substance P; cyclophilin; neurokinin 2 receptor; saredutant;
neurokinin 1 receptor; neurokinin; ovalbumin; neurokinin A; 3 (2 methoxybenzylamino)
2...

TERMS (UNCONTROLLED):

7/3,K/16 (Item 1 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

03918075 2007334435

Salmonid host response to infectious hematopoietic necrosis (IHN) virus: Cellular
receptors, viral control, and novel pathways of defence

ISSUE TITLE: Genetics in Aquaculture IX

Miller K.; Traxler G.; Kaukinen K.; Li S.; Richard J.; Ginther N.

Address: K. Miller, Department of Fisheries and Oceans, Pacific Biological Station,
3190 Hammond Bay Road, Nanaimo, BC V9T 6N7 , Canada

Email: millerk@pac.dfo-mpo.gc.ca

Journal : Aquaculture , 272/SUPPL. 1 (S217-S237) , 2007 , Netherlands

CODEN: AQCLA

ISSN: 0044-8486

Untitled

Publisher Item Identifier: S0044848607008435

Document Type: Article

Languages: English

Summary Languages: English

No. of References: 63

...gene GRASP cDNA microarrays. S. salar were exposed to the IHN virus in a waterborne challenge, and kidney samples from five fish sampled on each of days 0, 1, 5 and... ..potentially co-opted by the virus to enhance infectivity were also identified, including uPAR (angiogenesis), CypA (viral replication and infectivity), and BAF1 (viral protein biosynthesis). Perhaps the most notable finding was...

CLASSIFICATION CODE AND DESCRIPTION:

Modolecular Sequence Databank Number: ...Diseases of Aquatic Organisms

86.7.4 - IMMUNOLOGY AND INFECTIOUS DISEASES...

7/3,K/17 (Item 2 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

03914223 2007320180

Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication

Schneidewind A.; Brockman M.A.; Yang R.; Adam R.I.; Li B.; Le Gall S.; Rinaldo C.R.; Craggs S.L.; Allgaier R.L.; Power K.A.; Kuntzen T.; Tung C.-S.; LaBute M.X.; Mueller S.M.; Harter T.; McMichael A.J.; Goulder P.J.R.; Aiken C.; Brander C.; Kelleher A.D.; Allen T.M.

Address: T.M. Allen, MGH-East, CNY 6625, 149 13th Street, Charlestown, MA 02129 , United States

Email: tallen2@partners.org

Journal : Journal of Virology , 81/22 (12382-12393) , 2007 , United States

CODEN: JOVIA

ISSN: 0022-538X

Document Type: Article

Languages: English

Summary Languages: English

No. of References: 80

...Identifying the mechanism of the immune-mediated control may provide critical insights into HIV-1 vaccine development. Here, we illustrate that the CTL escape mutation RSUB264K in the HLA-B27-restrictedthe RSUB264K variant was rescued by the addition of cyclosporine A or infection of a cyclophilin A-deficient cell line. These data demonstrate a severe functional defect imposed by the RSUB264K... ..the inability of this variant to replicate efficiently in the presence of normal levels of cyclophilin A. We conclude that the impact of the RSUB264K substitution on capsid structure constrains viral...

CLASSIFICATION CODE AND DESCRIPTION:

Modolecular Sequence Databank Number: ...General functions and activation

86.7.4.5 - IMMUNOLOGY AND INFECTIOUS DISEASES...

7/3,K/18 (Item 3 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

03197544 2006018264

Nonmutated self-antigen-derived cancer vaccine peptides elicit an IgE-independent but mast cell-dependent immediate-type skin reaction without systemic anaphylaxis

Untitled

Yamada A.; Yano H.; Takao Y.; Ono T.; Matsumoto T.; Itoh K.
Address: Dr. A. Yamada, Cancer Vaccine Development Division, Kurume University
Research Center for Innovative Cancer Therapy, Asahi-machi 67, Kurume 830-0011, Japan

Email: akiyond@med.kurume-u.ac.jp

Journal : Journal of Immunology, 176/2 (857-863), 2006, United States

PUBLICATION DATE: January 15, 2006

CODEN: JOIMA

ISSN: 0022-1767

Document Type: Article

Languages: English Summary Languages: English

No. of References: 22

Nonmutated self-antigen-derived cancer vaccine peptides elicit an IgE-independent but mast cell-dependent immediate-type skin reaction without systemic...

we previously reported an unexpected phenomenon, i.e., several cancer vaccine peptides, including a cyclophilin B-derived peptide (CypB-84), elicited an immediate-type skin reaction in prevaccination skin tests... from the plasma by in vivo degradation. These results suggest that certain peptides of cancer vaccine candidates exhibit an IgE-independent but mast cell-dependent inflammatory response with no elicitation of...

CLASSIFICATION CODE AND DESCRIPTION:

Modolecular Sequence Databank Number: ...Tumour Immunotherapy

87.4.3 - CANCER RESEARCH...

7/3,k/19 (Item 4 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

03095916 2005247317

Identification of a peptide fragment of DSCR1 that competitively inhibits calcineurin activity in vitro and in vivo

Chan B.; Greenan G.; McKeon F.; Ellenberger T.

Address: F. McKeon, Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, United States

Email: frank.mckeeon@hms.harvard.edu

Journal : Proceedings of the National Academy of Sciences of the United States of America, 102/37 (13075-13080), 2005, United States

PUBLICATION DATE: September 13, 2005

CODEN: PNAS

ISSN: 0027-8424

Document Type: Article

Languages: English Summary Languages: English

No. of References: 40

...of the nuclear factor of activated T cells (NFAT) family of transcription factors during immune challenge. Calcineurin inhibitors, such as the cyclosporin A-cyclophilin A and FK506-FKBP12 complexes, regulate this enzymatic activity noncompetitively by binding at a site...

CLASSIFICATION CODE AND DESCRIPTION:

Modolecular Sequence Databank Number: ...Phosphatases

82.4.1 - PROTEIN BIOCHEMISTRY...

7/3,k/20 (Item 5 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

Page 14

Untitled

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

02823582 2004300608

The identification of genes from the oyster *Crassostrea gigas* that are differentially expressed in progeny exhibiting opposed susceptibility to summer mortality

Huvet A.; Herpin A.; Degremont L.; Labreuche Y.; Samain J.-F.; Cunningham C.

Email: ahuvet@ifremer.fr

Journal : Gene , 343/1 (211-220) , 2004 , Netherlands

PUBLICATION DATE: December 8, 2004

CODEN: GENED

ISSN: 0378-1119

Publisher Item Identifier: S037811190400575X

Document Type: Article

Languages: English Summary Languages: English

No. of References: 34

...function between resistant and susceptible progeny. In light of this, clones encoding homologues of cavortin, cyclophilin, isocitrate dehydrogenase, sodium glucose cotransporter, fatty acid binding protein, ATPase H⁺ transporting lysosomal protein, precerebellin... These transcripts were induced in resistant progeny when compared to their susceptible counterparts. A bacterial challenge of oysters resulted in the suppression of six of these transcripts in only those that ...

DESCRIPTORS:

Bacterial challenge; Bivalves; Differentially regulated genes; Oysters; Suppression subtractive hybridization

CLASSIFICATION CODE AND DESCRIPTION:

Molecular Sequence Databank Number: ...Invertebrates

91.4.2.1 - ECOLOGICAL AND ENVIRONMENTAL SCIENCES ...

7/3,K/21 (Item 6 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

02137493 2002218443

Phase 1 clinical study of cyclophilin B peptide vaccine for patients with lung cancer

Gohara R.; Imai N.; Rikimaru T.; Yamada A.; Hida N.; Ichiki M.; Kawamoto M.; Matsunaga K.; Ashihara J.; Yano S.; Tamura M.; Ohkouchi S.; Yamana H.; Oizumi K.; Itoh K.

Address: Dr. K. Itoh, Department of Immunology, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830-0011, Japan

Email: kyogo@med.kurume-u.ac.jp

Journal : Journal of Immunotherapy , 25/5 (439-444) , 2002 , United States

CODEN: JOIME

ISSN: 1053-8550

Document Type: Article

Languages: English Summary Languages: English

No. of References: 25

Phase 1 clinical study of cyclophilin B peptide vaccine for patients with lung cancer

Cyclophilin B (CypB) possesses two antigenic epitopes (CypBSUB84-92 and CypBgsUB91-99) recognized by HLA-A24...

Untitled

CLASSIFICATION CODE AND DESCRIPTION:

Molecular Sequence Databank Number: 87.4.3.2 - CANCER RESEARCH... Active specific
87.4.11 - CANCER RESEARCH...

7/3,K/22 (Item 7 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

01804875 2001166809

Activation and accumulation of B cells in TACI-deficient mice

Yan M.; Wang H.; Chan B.; Roose-Girma M.; Erickson S.; Baker T.; Tumas D.; Grewal I.S.; Dixit V.M.

Address: V.M. Dixit, Department of Molecular Oncology, Genentech Inc., San Francisco, CA 94080, United States

Email: dixit@gene.com

Journal : Nature Immunology, 2/7 (638-643), 2001, United States

CODEN: NIAMC

ISSN: 1529-2908

Document Type: Article

Languages: English Summary Languages: English

No. of References: 28

...lymphocyte stimulator (BLYS) binds two TNF receptor family members, transmembrane activator and calcium-modulating and cyclophilin ligand interactor (TACI) and B cell maturation molecule (BCMA). Mice that are transgenic for BLYS... TACISUP/- B cells hyperproliferated and produced increased amounts of immunoglobulins in vitro. In vivo antigen challenge resulted in enhanced antigen-specific antibody production. Thus, TACI may play an unexpected inhibitory role...

CLASSIFICATION CODE AND DESCRIPTION:

Molecular Sequence Databank Number: 86.3.4.3 - IMMUNOLOGY AND INFECTIOUS DISEASES...

7/3,K/23 (Item 8 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

01618053 2000277700

Limitations of cyclosporin A inhibition of the permeability transition in CNS mitochondria

Brustovetsky N.; Dubinsky J.M.

Address: Dr. J.M. Dubinsky, Depts. of Neuroscience and Physiol., Univ. of Minnesota Medical School, 6-145 Jackson Hall, 321 Church Street SE, Minneapolis, MN 55455, United States

Email: dubin001@tc.umn.edu

Journal : Journal of Neuroscience, 20/22 (8229-8237), 2000, United States

PUBLICATION DATE: November 15, 2000

CODEN: JNRSO

ISSN: 0270-6474

Document Type: Article

Languages: English Summary Languages: English

No. of References: 67

...failed to prevent mitochondrial swelling or PEG-induced shrinkage after swelling when the Casp2sup + challenge produced a strong, sustained depolarization. Thus in brain mitochondria CSA may be effective only as...

Untitled

DESCRIPTORS:

Permeability transition; Cyclosporin A; Excitotoxicity; Mitochondria; Neurodegeneration; Cyclophilin

CLASSIFICATION CODE AND DESCRIPTION:

Molecular Sequence Databank Number: ...Mitochondria
89.2.5.4 - CELL AND DEVELOPMENTAL BIOLOGY...

7/3,K/24 (Item 9 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

00945882 1998193582

Isolation and characterization of a cDNA corresponding to a stress-activated cyclophilin gene in *Solanum commersonii*

Meza-Zepeda L.A.; Baudo M.M.; Palva E.T.; Heino P.
Address: P. Heino, Department of Biosciences, Division of Genetics, University of Helsinki, FIN-00014 Helsinki, Finland
Email: Pekka.Heino@helsinki.fi

Journal: Journal of Experimental Botany, 49/325 (1451-1452), 1998, United Kingdom

CODEN: JEBOA

ISSN: 0022-0957

Document Type: Article

Languages: English Summary Languages: English

No. of References: 13

Isolation and characterization of a cDNA corresponding to a stress-activated cyclophilin gene in *Solanum commersonii*

A cDNA clone encoding cyclophilin (Cyp), was isolated from *Solanum commersonii* by utilizing subtractive hybridization. The corresponding gene was found... ..were exposed to low temperature, abscisic acid (ABA), drought, and wounding the amount of the cyclophilin mRNA was markedly increased. In addition, the gene was shown to be responsive to salicylic acid and pathogen challenge, suggesting a role in several different stress responses in plants.

DESCRIPTORS:

Stress; Cyclophilin; *Solanum commersonii*; Subtractive cloning

CLASSIFICATION CODE AND DESCRIPTION:

Molecular Sequence Databank Number: ...DNA and DNA synthesis

92.1.1.4 - PLANT SCIENCE... ..Drought, flooding, anoxia

92.4.3 - PLANT SCIENCE... ..Water Relations and Gas Exchange

92.7.2.4 - PLANT SCIENCE... ..Root and tuber crops

91.5.4.3 - ECOLOGICAL AND ENVIRONMENTAL SCIENCES...

7/3,K/25 (Item 1 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0082092043 EMBASE No: 2007527986

Improved protein identification efficiency by mass spectrometry using N-terminal chemical derivatization of peptides from *Angiostrongylus costaricensis*, a nematode with unknown genome

Untitled

Leon I.R.; Neves-Ferreira A.G.C.; Valente R.H.; Perales J. // Mota E.M.; Lenzi H.L. // Perales J.
Department of Physiology and Pharmacodynamics, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil // Department of Pathology, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil // Av. Brasil, 4365, Manguinhos, 21040-900, Rio de Janeiro, RJ, Brazil
Author email: jperales@ioc.fiocruz.br; jperales@ioc.fiocruz.br
Corresp. Author: Perales J.
Corresp. Author Affil: Av. Brasil, 4365, Manguinhos, 21040-900, Rio de Janeiro, RJ, Brazil
Corresp. Author email: jperales@ioc.fiocruz.br

Journal of Mass Spectrometry (J. Mass Spectrom.) (United Kingdom) October 1, 2007 , 42/10 (1363-1374)
CODEN: JMSPF ISSN: 10765174 eISSN: 10969888
Item Identifier (DOI): 10.1002/jms.1324
Document Type: Journal ; Conference Paper Record Type: Abstract
Language: English Summary language: English
Number of References: 32

...these data either manually and/or using de novo sequencing software can frequently be a challenge. To overcome this limitation when studying the proteome of adult *Angiostrongylus costaricensis*, a nematode with unknown genome, we have used chemical N-terminal derivatization of the tryptic peptides with 4-sulfophenyl isothiocyanate (SPITC) prior to MALDI-TOF/TOF MS. This methodology has recently been reported...
Drug Descriptors:

*
...ec; aspartic proteinase inhibitor--endogenous compound--ec; calreticulin--endogenous compound--ec; chaperonin--endogenous compound--ec; cyclophilin--endogenous compound--ec; galectin--endogenous compound--ec; glutathione transferase--endogenous compound--ec; heat shock protein ...
Medical Descriptors:

Drug Terms (Uncontrolled): 4 sulfophenyl isothiocyanate
Medical Terms (Uncontrolled):
CAS Registry Number: ..9028-86-8 (aldehyde dehydrogenase); 78769-62-7 (alpha tubulin); 126043-36-5 (cyclophilin); 50812-37-8 (glutathione transferase); 9024-82-2...
SECTION HEADINGS:

7/3,K/26 (Item 2 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0081669931 EMBASE No: 2007103459

Emerging host cell targets for hepatitis C therapy

He Y. // Duan W. // Tan S.-L.

Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, United States // School of Medicine, Deakin University, Waurn Ponds, Vic. 3217, Australia // Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, United States

Author email: yupeng.he@abbott.com

Corresp. Author: He Y.

Corresp. Author Affil: Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, United States

Corresp. Author email: yupeng.he@abbott.com

Drug Discovery Today (Drug Discov. Today) (United Kingdom) March 1, 2007 , 12/5-6 (209-217)

CODEN: DDTOF ISSN: 13596446

Untitled
Publisher Item Identifier: S1359644607000475
Item Identifier (DOI): 10.1016/j.drudis.2007.01.009
Document Type: Journal ; Review Record Type: Abstract
Language: English Summary language: English
Number of References: 110

...assembly, and intracellular pathways involving lipid biosynthesis, oxidative stress and innate immune response. A crucial challenge now is to manipulate such cellular targets pharmacologically for chronic HCV treatment, without being limited...

Drug Descriptors:

2,3 dihydro 2 oxo 3 (4,5,6,7 tetrahydro 1h indol 2 ylmethylene) 1h indole 5 sulfonic acid dimethylamide; acetylsalicylic... ..pharmacology--pd; canertinib; castanospermine 6 butyrate; cell surface receptor; cholesterol; cpg 10101--drug therapy--dt; cyclophilin; cyclosporin A--drug combination--cb; cyclosporin A--drug comparison--cm; cyclosporin A--drug concentration--cr...

Medical Descriptors:

CAS Registry Number: ...141117-12-6 (castanospermine 6 butyrate); 57-88-5 (cholesterol); 126043-36-5 (cyclophilin); 59865-13-3...

SECTION HEADINGS:

7/3,K/27 (Item 3 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0081376989 EMBASE No: 2006439736

Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: A microarray validation study

Schultz I.J.; Willems J.L.; Swinkels D.W.; De Kok J.B. // Wester K. // Straatman H.; Kiemeny L.A. // Kiemeny L.A.; Witjes J.A. // Babjuk M. // Mares J. // Malmstrom P.-U. // Swinkels D.W.

Department of Clinical Chemistry, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands // Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University Hospital, Uppsala, Sweden // Department of Epidemiology and Biostatistics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands // Department of Urology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands // Department of Urology, General Faculty Hospital, Charles University, Prague, Czech Republic // Institute of Biology and Medical Genetics, Charles University, Prague, Czech Republic // Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden // AKC/441, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, Netherlands

Author email: d.swinkels@akc.umcn.nl; d.swinkels@akc.umcn.nl

Corresp. Author: Swinkels D.W.

Corresp. Author Affil: AKC/441, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, Netherlands

Corresp. Author email: d.swinkels@akc.umcn.nl

International Journal of Cancer (Int. J. Cancer) (United States) October 15, 2006 , 119/8 (1915-1919)

CODEN: IJCN A ISSN: 00207136 eISSN: 10970215

Item Identifier (DOI): 10.1002/ijc.22059

Document Type: Journal ; Article Record Type: Abstract

Language: English Summary language: English

Number of References: 39

...expression level as cut-off, a sensitivity of 69.6% and a specificity of 71.4% were obtained for the identification of patients with short or prolonged recurrence-free periods, respectively... ..shown by Dyrskjot et al. The discovery of accurate recurrence predictive markers, therefore, remains a challenge. (c) 2006 Wiley-Liss, Inc.

Untitled

Drug Descriptors:

complementary DNA; cyclophilin A; leukotriene B4; oxidoreductase; phosphoprotein; RNA; unclassified drug
Medical Descriptors:

7/3,K/28 (Item 4 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0080631596 EMBASE No: 2005275888

Induction of transplantation tolerance - The potential of regulatory T cells

Akl A.; Luo S.; Wood K.J.

Nuffield Department of Surgery, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, United Kingdom

Author email: shiqiao.luo@surgery.ox.ac.uk

Corresp. Author: Luo S.

Corresp. Author Affil: Nuffield Department of Surgery, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, United Kingdom

Corresp. Author email: shiqiao.luo@surgery.ox.ac.uk

Transplant Immunology (Transplant Immunol.) (Netherlands) August 1, 2005 , 14/3-4 SPEC. ISS. (225-230)

CODEN: TRIME ISSN: 09663274

Publisher Item Identifier: S0966327405000407

Item Identifier (DOI): 10.1016/j.trim.2005.03.011

Document Type: Journal ; Conference Paper Record Type: Abstract

Language: English Summary language: English

Number of References: 76

...maintenance immune suppressive drug therapy has led to the uncovering of a tolerant state. The challenge of achieving improved monitoring of all transplant patients may allow tailoring of immunosuppression in a...

Drug Descriptors:

...CD28 antigen--endogenous compound--ec; CD4 antigen--endogenous compound --ec; CD8 antigen--endogenous compound--ec; cyclophilin--endogenous compound--ec; cyclosporin--drug therapy--dt; cyclosporin--pharmacology--pd; cytoplasmic receptor--endogenous compound--ec; cytotoxic T lymphocyte antigen 4--endogenous compound--ec; fingolimod--drug therapy--dt; fingolimod--pharmacology--pd; fk 506 binding protein--endogenous... ..ec; interleukin 2 receptor--endogenous compound--ec; interleukin 2 receptor alpha--endogenous compound--ec; interleukin 4--endogenous compound--ec; interleukin 5--endogenous compound--ec; mycophenolic acid 2 morpholinoethyl ester--drug therapy...

Medical Descriptors:

CAS Registry Number: 126043-36-5 (cyclophilin); 79217-60-0 (cyclosporin);

162359-56-0 (fingolimod); 82115-62-6 (gamma interferon); 148157-34...

SECTION HEADINGS:

7/3,K/29 (Item 5 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0079813472 EMBASE No: 2003424187

Novel effects on memory observed following unilateral intracranial administration of okadaic acid, cyclosporin A, FK506 and [MeVal SUP 4]CyA

Bennett P.C.; Moutsoulas P.; Perini E.; Ng K.T. // Lawen A.

Department of Psychology, Sch. Psychol., Psychiat./Psychol. M., Monash University, P.O. Box 197, Caulfield East, Vic. 3145, Australia // Dept. of Biochem./Molecular

Untitled
Biology, School of Biomedical Sciences, Monash University, Monash, Vic., Australia
Author email: p.bennett@med.monash.edu.au
Corresp. Author: Bennett P.C.
Corresp. Author Affil: Department of Psychology, Sch. Psychol., Psychiat./Psychol.
M., Monash University, P.O. Box 197, Caulfield East, Vic. 3145, Australia
Corresp. Author email: p.bennett@med.monash.edu.au

Brain Research (Brain Res.) (Netherlands) October 24, 2003 , 988/1-2 (56-68)

CODEN: BRREA ISSN: 00068993
Item Identifier (DOI): 10.1016/S0006-8993(03)03344-4
Document Type: Journal ; Article Record Type: Abstract
Language: English Summary language: English
Number of References: 85
...memory observed following unilateral intracranial administration of okadaic acid, cyclosporin A, FK506 and [Meval SUP 4]Cya

...previously following bilateral administration of okadaic acid (OA), cyclosporin A (Cya), FK506 and [Meval SUP 4]Cya can be attributed to their action in just one hemisphere. OA, at a concentration... administration of FK506 (20 nM), which also inhibits PP2B and PPIase activity, and [Meval SUP 4]Cya (5 nM), which inhibits PPIase activity but not PP2B activity. Administration of Cya (20 nM) and FK506, but not [Meval SUP 4]Cya, in the right hemisphere leads to a transient period of memory loss from 10... post-training. These results confirm significant roles for phosphatases and PPIases in memory processing but challenge previous conclusions drawn on the basis of bilateral drug administration protocols. (C) 2003 Elsevier B...

Drug Descriptors:

*cyclophilin--endogenous compound--ec; *cyclosporin A--drug administration--ad; *cyclosporin A--drug toxicity--to; *cyclosporin A...
Drug Terms (Uncontrolled): cyclosporin A [4 methylvaline]--drug administration--ad; cyclosporin A [4 methylvaline]--drug toxicity--to; cyclosporin A [4 methylvaline]--intracerebroventricular drug administration--cv; cyclosporin A [4 methylvaline]--pharmacology--pd
Medical Terms (Uncontrolled):
CAS Registry Number: 137951-12-3 (calcineurin); 126043-36-5 (cyclophilin); 59865-13-3...
SECTION HEADINGS:

7/3,K/30 (Item 6 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(C) 2008 Elsevier B.V. All rights reserved.

0079579474 EMBASE No: 2003286716

Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients

Mine T.; Hida N.; Imai N.; Azuma K.; Katagiri K.; Nishikori M.; Sukehiro A. ; Nakagawa M.; Itoh K. // Mine T.; Shirouzu K.; Yamana H. // Gouhara R.; Rikimaru T.; Aizawa H. // Yamada A.

Department of Immunology, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan // Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan // 1st Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan // Cancer Vaccine Development Division, Kurume University, Res. Ctr. for Innov. Cancer Therapy, 67 Asahi-machi, Kurume 830-0011, Japan
Author email: mine@med.kurume-u.ac.jp; mine@med.kurume-u.ac.jp
Corresp. Author: Mine T.

Corresp. Author Affil: Department of Immunology, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan
Corresp. Author email: mine@med.kurume-u.ac.jp

Untitled

Cancer Science (Cancer Sci.) (Japan) June 1, 2003 , 94/6 (548-556)
CODEN: CSACC ISSN: 13479032
Document Type: Journal ; Article Record Type: Abstract
Language: English Summary language: English
Number of References: 31

Recent clinical trials of peptide vaccine for cancer patients have rarely resulted in tumor regression. One of the reasons for this... ..against the immunized peptides and tumor cells were observed in the post-vaccination PBMCs from 4 of 8 and 3 of 10 patients tested, respectively. Peptide-specific IgG became detectable in post-vaccination sera in 4 of 10 patients tested, and these 4 patients had a long progression-free survival. Furthermore, the median survival time of 9 patients...
Drug Descriptors:

*
cancer vaccine--adverse drug reaction--ae; cancer vaccine --drug therapy--dt; cancer vaccine--pharmacology--pd; carboplatin --drug combination--cb; carboplatin--drug therapy--dt; carboplatin --pharmacology--pd; cisplatin--drug combination--cb; cisplatin--drug therapy--dt; cisplatin--pharmacology--pd; cyclophilin--drug therapy --dt; cyclophilin--pharmacology--pd; cytarabine--drug combination --cb; cytarabine--drug therapy--dt; cytarabine--pharmacology--pd; docetaxel --drug...

Medical Descriptors:

CAS Registry Number: ...96081-74-2 (cisplatin); 126043-36-5 (cyclophilin); 147-94-4...

SECTION HEADINGS:

7/3,K/31 (Item 7 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(C) 2008 Elsevier B.V. All rights reserved.

0079533184 EMBASE No: 2003239603

GM-CSF-secreting melanoma vaccines

Issue Title: Melanoma

Dranoff G. // Dranoff G. // Dranoff G.

Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States // Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States // Dana-Farber Cancer Institute, Dana 510E, 44 Binney Street, Boston, MA 02115 , United States

Author email: glenn.dranoff@dfci.harvard.edu; glenn.dranoff@dfci.harvard.edu; glenn.dranoff@dfci.harvard.edu

Corresp. Author: Dranoff G.

Corresp. Author Affil: Dana-Farber Cancer Institute, Dana 510E, 44 Binney Street, Boston, MA 02115 , United States

Corresp. Author email: glenn.dranoff@dfci.harvard.edu

Oncogene (Oncogene) (United Kingdom) May 19, 2003 , 22/20 (3188-3192)

CODEN: ONCNE ISSN: 09509232

Item Identifier (DOI): 10.1038/sj.onc.1206459

Document Type: Journal ; Review Record Type: Abstract

Language: English Summary language: English

Number of References: 51

Drug Descriptors:

* cytotoxic T lymphocyte antigen 4; *gene product--drug development --dv; *gene product--pharmacology--pd; *melanoma vaccine--clinical trial--ct; *melanoma vaccine--drug development--dv; *melanoma vaccine--pharmacology--pd; *melanoma vaccine--subcutaneous drug administration--sc; *tumor antigen--endogenous compound--ec

...CD1d antigen--endogenous compound--ec; CD4 antigen--endogenous compound --ec; CD8 antigen--endogenous compound--ec; cyclophilin; eotaxin; Flt3 ligand; gamma interferon; granulocyte colony stimulating factor; granulocyte macrophage colony stimulating factor--pharmacology... ...1; interleukin 1 receptor; interleukin 10;

Untitled
interleukin 12; interleukin 18; interleukin 2; interleukin 3; interleukin 4;
interleukin 5; interleukin 6; interleukin 7; stem cell factor; tumor necrosis factor
alpha ; unclassified drug...
Medical Descriptors:
Drug Terms (Uncontrolled): ...651--drug development--dv; atp 651--pharmacology--pd;
granulocyte macrophage colony stimulating factor secreting melanoma vaccine --drug
development--dv; granulocyte macrophage colony stimulating factor secreting melanoma
vaccine--pharmacology--pd
Medical Terms (Uncontrolled):
CAS Registry Number: 126043-36-5 (cyclophilin); 171404-15-2 (Flt3 ligand);
82115-62-6 (gamma interferon); 138415-13-1 (interleukin 12...
SECTION HEADINGS:

7/3,K/32 (Item 8 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0078042847 EMBASE No: 2000092093

Preliminary profile of the *Cryptosporidium parvum* genome: An expressed sequence
tag and genome survey sequence analysis

Strong W.B.; Nelson R.G. // Strong W.B.; Nelson R.G. // Nelson R.G.
Division of Infectious Diseases, San Francisco General Hospital, San Francisco,
CA, United States // Department of Medicine, University of California, San
Francisco, CA 94143-0811, United States // Dept. of Pharmaceutical Chemistry,
University of California, San Francisco, CA 94143-0811, United States
Author email: malaria@itsa.ucsf.edu; malaria@itsa.ucsf.edu; malaria@itsa.ucsf.edu
Corresp. Author: Nelson R.G.
Corresp. Author Affil: Division of Infectious Diseases, San Francisco General
Hospital, San Francisco, CA, United States
Corresp. Author email: malaria@itsa.ucsf.edu

Molecular and Biochemical Parasitology (Mol. Biochem. Parasitol.) (Netherlands
) March 15, 2000 , 107/1 (1-32)
CODEN: MBIPD ISSN: 01666851
Publisher Item Identifier: S016668519900225X
Item Identifier (DOI): 10.1016/S0166-6851(99)00225-X
Document Type: Journal ; Article Record Type: Abstract
Language: English Summary language: English
Number of References: 103

...development of such therapies. To accelerate gene discovery and identify genes
encoding potential drug and vaccine targets we constructed sporozoite cDNA and
genomic DNA sequencing libraries from the Iowa isolate of... ..totalled one megabase
(1 mb) of unique genomic sequence indicating that ~10% of the 10.4 mb *C. parvum*
genome has been sequence tagged in this gene discovery expedition. The tags...

Drug Descriptors:

*adenosylhomocysteinase; *cyclophilin; *fatty acid synthase; *histone deacetylase;
*polyketide; *thrombospondin
CAS Registry Number: ...987-65-5 (adenosine triphosphate); 9025-54-1
(adenosylhomocysteinase); 126043-36-5 (cyclophilin); 9045-77-6 (fatty acid
synthase); 9076-57-7 (histone deacetylase)

SECTION HEADINGS:

7/3,K/33 (Item 9 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0077771686 EMBASE No: 1999257990

Enhanced transcription factor DNA binding and gene expression induced by arsenite
or arsenate in renal slices

Untitled

Parrish A.R.; Xing Hui Zheng; Turney K.D.; Younis H.S.; Gandolfi A.J.
Dept. of Pharmacology and Toxicology, College of Pharmacy, University of Arizona,
Tucson, AZ 85721, United States
Corresp. Author: Gandolfi A.J.
Corresp. Author Affil: Dept. of Pharmacology and Toxicology, College of Pharmacy,
University of Arizona, Tucson, AZ 85721, United States
Corresp. Author email: gandolfi@pharmacy.arizona.edu

Toxicological Sciences (Toxicol. Sci.) (United States) August 9, 1999 , 50/1
(98-105)

CODEN: TOSCF ISSN: 10966080
Document Type: Journal ; Article Record Type: Abstract
Language: English Summary language: English
Number of References: 52

...90 were observed. However, induction of heine oxygenase-1 (Hsp 32) was seen following a 4-h challenge with As(III), but not with As(V). As(III) and As(V) induced DNA binding of AP-1 at 2- and 4-h exposure; following a 6-h exposure there was no difference. Although no alteration in... ..V), albeit at a later time point (6 h). These results suggest that acute arsenic challenge, by either As(III) or As(V), is associated with discrete alterations in the activity...

Drug Descriptors:

*
cyclophilin; heat shock protein 60; heat shock protein 70; heat shock protein 90; heme oxygenase; potassium...

Medical Descriptors:

CAS Registry Number: ...15502-74-6 (arsenic trioxide); 126043-36-5 (cyclophilin); 9059-22-7 (heme oxygenase); 7440-09-7 (potassium)

SECTION HEADINGS:

7/3,K/34 (Item 1 from file: 156) Links

Fulltext available through: STIC Full Text Retrieval Options

TCFile

(c) format only 2008 Dialog. All rights reserved.

187218 NLM Doc No: DART/TER/3000706 Sec. Source ID: DART/TER/3000706

Effects of polybrominated diphenylether (PBDE) on reproductive organ and brain development and gene expression in rats.

Lichtensteiger W; Ceccatelli R; Faass O; Fleischmann I; Schlumpf M
Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.

Source: Toxicologist 2003 Mar;72(S-1):133

Journal Name: Toxicologist Pub. Year: 2003 ISSN: 0731-9193

Document type: MEETING ABSTRACT

Languages: ENGLISH

Record type: Completed

...have increased during the last decade. We are comparing developmental actions of PBDE99 (2,2',4,4',5-pentabDE) and the PCB mixture, Aroclor 1254. PBDE99 (1 or 10 mg/kg/day)... ..PBDE99 exposure affected sex hormone target gene mRNA levels determined by Real Time PCR (reference cyclophilin), IGF-I mRNA in ventral prostate and uterus, progesterone receptor mRNA in uterus, androgen receptor... ..dorsal prostate. mRNA levels in sexually dimorphic brain regions, and mRNA expression after acute estrogen challenge in gonadectomized offspring, are under investigation. Our data indicate that PBDE99 can interfere with sexual... (

7/3,K/35 (Item 1 from file: 370) Links

Science

(c) 1999 AAAS. All rights reserved.

00507548 (USE 9 FOR FULLTEXT)

Harnessing the Biosynthetic Code: Combinations, Permutations, and Mutations

Page 24

Untitled

Cane, David E.; walsh, Christopher T.; Khosla, Chaitan
D. E. Cane, Department of Chemistry, Box H, Brown University, Providence, RI
02912-9108, USA. C. T. walsh, Department of Biological Chemistry and Molecular
Pharmacology, Harvard Medical School, Boston, MA 02115, USA. C. Khosla, Departments
of Chemical Engineering, Chemistry, and Biochemistry, Stanford University, Stanford,
CA 94305-5025, USA.
Science Vol. 282 5386 pp. 63
Publication Date: 10-02-1998 (981002) Publication Year: 1998
Document Type: Journal ISSN: 0036-8075
Language: English
Section Heading: REVIEW
Word Count: 4048 (THIS IS THE FULLTEXT)

Text:

...convenience with which the primary amino acid sequences of their
corresponding binding proteins, FKBP and cyclophilin, can be
altered. What is the state-of-art in the manipulation of microbial natural
...positions of the chain. Likewise, the presence of methyl transferase
domains in modules 2, 3, 4, 5, 7, 8, and 10 of the cyclosporin
synthetase results in N-methylation of the...

References and Notes:

...4. Many polyketides, particularly aromatic polyketides such as tetracycline, are
biosynthesized by structurally simpler polyketide synthases...not clear. Developing
strategies to overcome these deleterious effects on chain transfer represents a
major challenge. ;

7/3,k/36 (Item 1 from file: 399) Links

CA SEARCH(R)

(C) 2008 American Chemical Society. All rights reserved.

142428768 CA: 142(23)428768e PATENT
AIDS vaccine comprising HIV capsid protein cyclophilin A-binding site, fragment,
mRNA or DNA/RNA and a variety of immune stimulant
Inventor (Author): Karp, Nelson M.
Location: USA
Assignee: NMK Research, LLC
Patent: PCT International ; WO 200540349 A2 Date: 20050506
Application: WO 2004US35210 (20041025) *US 2003PV513827 (20031023)
Pages: 77 pp.
CODEN: PIXXD2

Language: English

Patent Classifications:

Class: C12N-000/A

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA;
CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG;
MK; MN; MW; MX; MY; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK;
SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW
Designated Regional: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM;
AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB;
GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA;
GN; GQ; GW; ML; MR; NE; SN; TD; TG

7/3,k/37 (Item 2 from file: 399) Links

Fulltext available through: STIC Full Text Retrieval Options

Page 25

Untitled

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

140075596 CA: 140(6)75596s JOURNAL
In vitro cellular and humoral responses to *Schistosoma mansoni* vaccine candidate
antigens
Author: Al-Sherbiny, Maged; Osman, Ahmed; Barakat, Rashida; El Morshedy, Hala;
Bergquist, Robert; Olds, Richard
Location: Faculty of Science, Department of Zoology, Cairo University/Egyptian
Reference Diagnostic Center (ERDC/VACSERA), Cairo, Egypt, 12311
Journal: Acta Trop.
Date: 2003
Volume: 88 Number: 2 Pages: 117-130
CODEN: ACTRAQ
ISSN: 0001-706X
Publisher Item Identifier: 0001-706X(03)00195-5
Language: English
Publisher: Elsevier Science B.V.

7/3,K/38 (Item 1 from file: 35) Links
Dissertation Abs Online
(c) 2008 ProQuest Info&Learning. All rights reserved.
01664556 ORDER NO: AADMQ-29641
CYTOKINES IN RAT LUNG IN RESPONSE TO ANTIGEN CHALLENGE

Author: AL-ASSAAD, ALI-SAMER
Degree: M.SC.
Year: 1997
Corporate Source/Institution: MCGILL UNIVERSITY (CANADA) (0781)
Source: Volume 37/01 of MASTERS ABSTRACTS. of Dissertations Abstracts International.

PAGE 247 . 100 PAGES
ISBN: 0-612-29641-5
CYTOKINES IN RAT LUNG IN RESPONSE TO ANTIGEN CHALLENGE

In humans, it has been demonstrated that Th-2 type cytokines (interleukin (IL)-4 and IL-5) are highly expressed in bronchial biopsies from asthmatics. Our hypothesis is that... ..cytokine response comprising Th-2 cytokines occurs during the late airway response (LR) after antigen challenge and that a different Th-1 response (interferon (IFN)- γ) is related to the absence of a physiological response after antigen challenge. We have tested this hypothesis in different strains of rats, Brown Norway (BN) rats are high IgE producers that develop LR and increased airway responsiveness after antigen challenge, whilst Sprague Dawley (SD) rats are low IgE producers that do not develop physiological changes following antigen challenge. We assessed the expression of cytokines in these two strains of rats using semi-quantitative... ..the rats underwent general anaesthesia and were killed either immediately or eight hours after OA challenge. The lungs were frozen in liquid nitrogen for total RNA preparation. cDNA was prepared from total RNA, and mRNA expression for IL-4, IL-5 and IFN- γ was assessed before and after challenge in BN and SD rats using Cyclophilin as a housekeeping gene. (Abstract shortened by UMI.)

7/3,K/39 (Item 1 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000692516 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers from La Sapienza University report recent findings in enzyme research

Untitled

Proteomics Weekly, November 26, 2007, p.123

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
407

...TEXT: mice infected with *Schistosoma mansoni*." "Given the well established interaction between cyclosporin A and the cyclophilin superfamily of peptidylprolyl cis-trans isomerases, we solved the structure of cyclophilin A from *S. mansoni* (SmCypA) by x-ray crystallography in the reduced and oxidized states...

...C-terminal cysteines (Cys-122 and Cys-126). This is the first example of a cyclophilin containing this disulfide bridge. Parallel functional studies suggest a mechanism for regulation of SmCypA activity...

...7) M-1 s(-1), and it is inhibited by cyclosporin A (IC50 of 14 +/- 4 nM)," wrote L.J. Gourlay and colleagues, La Sapienza University. The researchers concluded: "The lack of conservation of this cysteine couple within the CypA superfamily, their close proximity to the active site, and the importance of thiol groups for peptidyl-prolyl cis-trans isomerase activity render this structural feature a challenge for the development of alternative and more effective anti-schistosomiasis inhibitors and may in addition..."

Journal of Biological Chemistry (The three-dimensional structure of two redox states of cyclophilin a from *Schistosoma mansoni* - Evidence for redox regulation of peptidyl-prolyl cis-trans isomerase activity...

7/3,K/40 (Item 2 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000558340 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Research by Medical University of Vienna, Austria, advances understanding of human health

Science Letter, July 3, 2007, p.4934

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1042

...TEXT: developing directions of research. Study 1: Research findings, "Rct1, a nuclear RNA recognition motif-containing cyclophilin, regulates phosphorylation of the RNA polymerase II C-terminal domain," are

Untitled

discussed in a new...

...and coordinates it with pre-mRNA processing. We show here that Rct1, a nuclear multidomain cyclophilin from *Schizosaccharomyces pombe*, is encoded by an essential gene that interacts with the CTD and...

...concluded: "These data, together with the pleiotropic phenotype upon Rct1 deregulation, suggest that this multidomain cyclophilin is an important player in maintaining the correct phosphorylation code of the CTD and thereby..."

...published their study in *Molecular and Cellular Biology* (Rct1, a nuclear RNA recognition motif-containing cyclophilin, regulates phosphorylation of the RNA polymerase II C-terminal domain.

... with pregnancy loss [odds ratio (OR) 9.6, 95% confidence interval (CI) 1.6-56.4]. This risk was even higher in the subgroup of women (n=16) with more than two miscarriages or fetal loss after the first trimester [OR 13.1, 95% CI 1.4-126.3]." "There was no significant association between anticardiolipin antibodies and pregnancy loss [OR 3...

...20, A-1090 Vienna, Austria. erika.jensen-jarolim@meduniwien.ac.at.

Keywords: Vienna, Austria, Cancer vaccine, Vaccine Development, Vaccine Efficacy, Epitope Mimic, Immunology, Immunotherapy, Oncology, Tumor-Associated Carbohydrate Antigen, Proteomics. This article was prepared...

7/3,K/41 (Item 3 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000483025 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Medical findings published by University of Padua, Italy

Biotech Business Week, March 26, 2007, p.1229

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
934

...TEXT: plating cells on collagen VI, and by treatment with cyclosporin A or with the specific cyclophilin inhibitor methylAla(3)ethylVal(4)-cyclosporin, which does not affect calcineurin activity. Here we demonstrate that mitochondrial dysfunction plays an...

...a pharmacological therapy of Ullrich congenital muscular dystrophy with cyclosporin A and methylAla(3)ethylVal(4) cyclosporin." Angelin and colleagues published their study in *Proceedings of the National Academy of Sciences*...

... the University of Padua. They continued, "Prevalence of positive antibodies to rubella in females (97.4%) was significantly higher (p<0.00) than males (87.5%), but only if aged 25...

...50%; in addition, about 40.0% of vaccinated subjects eluded control

Untitled
after vaccination. Seroconversion after vaccine appeared high for
rubella, mumps, and measles (92.3, 88.9, and 88.1%, respectively...

...low for varicella (43.8%)," the authors noted. Trevisan and associates
published their study in Vaccine (Prevalence of childhood
exanthematic disease antibodies in paramedical students: Need of
vaccination. Vaccine, 2006;24(2):171-176). For additional
information, contact Andrea Trevisan, Department of Environmental Medicine
...

...35128 Padova, Italy. andrea.trevisan@unipd.it. Keywords: Padua, Italy,
Occupational Health, Emergency Medicine, Pediatric Vaccine,
Measles-Mumps-Rubella Vaccine, Chickenpox Vaccine, Varicella
Vaccine, Varicella Virus, Immunotherapy, Nosocomial Infection,
Public Health. This article was prepared by Biotech Business Week...

7/3,K/42 (Item 4 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000446645 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Study results from Kurume University, Japan, update cancer treatment
knowledge

Cancer Vaccine Week, February 19, 2007, p.11

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1084

...TEXT: advances have been reported from Kurume University, Japan.

Study 1: Data detailed in "Anti-cancer vaccine candidates in
specific immunotherapy for bladder carcinoma" have been presented.
According to recent research from...

... BC patients."

Komohara and colleagues published their study in International Journal
of Oncology (Anti-cancer vaccine candidates in specific
immunotherapy for bladder carcinoma. International Journal of Oncology,
2006;29(6):1555...

...For additional information, contact Y. Komohara, Kurume University
Research Center for Innovative Cancer Therapy, Cancer Vaccine
Development Division, Kurume University School of Medicine, Kurume, Fukuoka
830-0011, Japan.

Study 2: Nonmutated self-antigen-derived cancer vaccine
peptides elicit an IgE-independent, but mast cell-dependent, immediate-type
skin reaction without systemic...

...According to researchers in Japan, "we previously reported an unexpected
phenomenon, i.e., several cancer vaccine peptides, including a
cyclophilin B-derived peptide (CypB-84), elicited an immediate-type
skin reaction in prevaccination skin tests...

Untitled

...vivo degradation," the authors noted.

They concluded, "These results suggest that certain peptides of cancer vaccine candidates exhibit an IgE-independent but mast cell-dependent inflammatory response with no elicitation of...

...and associates published their study in the Journal of Immunology (Nonmutated self-antigen-derived cancer vaccine peptides elicit an IgE-independent but mast cell-dependent immediate-type skin reaction without systemic...

...857-863).

For additional information, contact Akira Yamada, Research Center for Innovative Cancer Therapy, Cancer Vaccine Development Division, and Center of the 21st Century Center of Excellence Program for Medical Science ...

...in specific immunotherapy for a wide variety of tumor types. Int J Oncol, 2005;27(4):981-8).

Additional information can be obtained by contacting Y. Arima, Kurume University of School...

...Blood, Renal Cancer, Renal Carcinoma, Tumors, Women's Health.

This article was prepared by Cancer Vaccine Week editors from staff and other reports. Copyright 2007, Cancer Vaccine Week via NewsRx.com & NewsRx.net.

7/3,K/43 (Item 5 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000441050 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Data from Kurume University, Japan, provide new medical insights

Health & Medicine Week, February 12, 2007, p.4063

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1029

... tumors. A 69-year-old man was found to have a mass lesion measuring approximately 4 cm in diameter in the pancreatic head on ultrasound, abdominal dynamic CT, and percutaneous transhepatic...

...ml) and to a lesser extent in Crohn disease (active disease, 66 ng/ml, 44.4-87.6 ng/ml; inactive disease, 63 ng/ml, 43.5-82.5 ng/ml...

...Medicine 2, 67 Asahi machi, Fukuoka 8300011, Japan.

Study 3: Nonmutated self-antigen-derived cancer vaccine peptides elicit an IgE-independent, but mast cell-dependent, immediate-type skin reaction without systemic...

...According to researchers in Japan, "We previously reported an unexpected
Page 30

Untitled
phenomenon, i.e., several cancer vaccine peptides, including a
cyclophilin B-derived peptide (CypB-84), elicited an immediate-type
skin reaction in prevaccination skin tests...

...vivo degradation," the authors noted.

They concluded, "These results suggest that certain peptides of cancer
vaccine candidates exhibit an IgE-independent but mast
cell-dependent inflammatory response with no elicitation of...

...and associates published their study in the Journal of Immunology
(Nonmutated self-antigen-derived cancer vaccine peptides elicit an
IgE-independent but mast cell-dependent immediate-type skin reaction
without systemic...

...857-863).

For additional information, contact Akira Yamada, Research Center for
Innovative Cancer Therapy, Cancer Vaccine Development Division, and
Center of the 21st Century Center of Excellence Program for Medical
Science, Kurume University, Kurume, Japan.

Keywords: Kurume, Japan, Vaccine Safety, Cancer Vaccine,
Vaccine Development, Allergy Medicine, Anaphylaxis, Immunology,
Immunotherapy, Oncology, Proteomics.

This article was prepared by Health & Medicine...

DESCRIPTORS: Allergy Medicine; Anaphylaxis; Biotechnology; Cancer
Vaccine; Cancer Vaccines; Immunology;
Immunotherapy; Japan; Kurume; Kurume University;
Oncology; Peptide; Pharmace; Proteins; Proteomics;
Vaccine Development; Vaccine Safety; All
News; Professional News; General Health

7/3,K/44 (Item 6 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000426260 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Studies from University of Alabama, U.S., highlight most recent research

Health & Medicine Week, January 29, 2007, p.4454

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1076

... implanted CUF probes into tumor masses at the progressive and
regressive stage. Five secreted proteins (cyclophilin-A, S100A4,
profilin-1, thymosin beta 4 and 10), previously associated with
tumor progression, were identified from tumor masses at the progressive...
...receptor 9 agonists promote cellular invasion by increasing matrix
metalloproteinase activity. Mol Cancer Res, 2006;4(7):437-447).

For additional information, contact K.S. Selander, University of
Alabama, Department of...

Untitled

DESCRIPTORS: Alabama; Apoptosis; Astrocytoma; Birmingham; Breast Cancer; Cancer Therapy; Cancer Vaccine; Matrix Metalloproteinases; Molecular Targets; Oncology; Oncology; Receptor Agonists; Toll-Like Receptors; U S ; United States...

7/3,K/45 (Item 7 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000398203 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Research reports on cancer treatment from Kurume University, Japan, provide new insights

Cancer Vaccine Week, January 8, 2007, p.30

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1086

...TEXT: been reported by scientists from Kurume University, Japan.

Study 1: Data detailed in "Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma" have been presented. According to recent research from...

... BC patients."

Komohara and colleagues published their study in International Journal of Oncology (Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma. International Journal of Oncology, 2006;29(6):1555...

...For additional information, contact Y. Komohara, Kurume University Research Center for Innovative Cancer Therapy, Cancer Vaccine Development Division, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.

Study 2: Nonmutated self-antigen-derived cancer vaccine peptides elicit an IgE-independent, but mast cell-dependent, immediate-type skin reaction without systemic...

...According to researchers in Japan, "We previously reported an unexpected phenomenon, i.e., several cancer vaccine peptides, including a cyclophilin B-derived peptide (CypB-84), elicited an immediate-type skin reaction in prevaccination skin tests...

...vivo degradation," the authors noted.

They concluded, "These results suggest that certain peptides of cancer vaccine candidates exhibit an IgE-independent but mast cell-dependent inflammatory response with no elicitation of...

...and associates published their study in the Journal of Immunology (Nonmutated self-antigen-derived cancer vaccine peptides elicit an IgE-independent but mast cell-dependent immediate-type skin reaction without systemic...

Untitled

...857-863).

For additional information, contact Akira Yamada, Research Center for Innovative Cancer Therapy, Cancer Vaccine Development Division, and Center of the 21st Century Center of Excellence Program for Medical Science ...

...in specific immunotherapy for a wide variety of tumor types. Int J Oncol, 2005;27(4):981-8).

Additional information can be obtained by contacting Y. Arima, Kurume University of School...

...Blood, Renal Cancer, Renal Carcinoma, Tumors, Women's Health.

This article was prepared by Cancer Vaccine Week editors from staff and other reports. Copyright 2007, Cancer Vaccine Week via NewsRx.com & NewsRx.net.

7/3,K/46 (Item 8 from file: 135) Links

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

0000374210 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Results of recent studies reported by Kurume University, Japan

Life Science Weekly, December 5, 2006, p.558

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English

RECORD TYPE: FULLTEXT

Word Count:

1191

... Medicine, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.

Study 2: Nonmutated self-antigen-derived cancer vaccine peptides elicit an IgE-independent, but mast cell-dependent, immediate-type skin reaction without systemic...

...According to researchers in Japan, "we previously reported an unexpected phenomenon, i.e., several cancer vaccine peptides, including a cyclophilin B-derived peptide (CypB-84), elicited an immediate-type skin reaction in prevaccination skin tests...

...vivo degradation," the authors noted.

They concluded, "These results suggest that certain peptides of cancer vaccine candidates exhibit an IgE-independent but mast cell-dependent inflammatory response with no elicitation of...

...and associates published their study in the Journal of Immunology (Nonmutated self-antigen-derived cancer vaccine peptides elicit an IgE-independent but mast cell-dependent immediate-type skin reaction without systemic...

...857-863).

For additional information, contact Akira Yamada, Research Center for Innovative Cancer Therapy, Cancer Vaccine Development Division, and

Untitled
Center of the 21st Century Center of Excellence Program for Medical Science
...

...in specific immunotherapy for a wide variety of tumor types. Int J
Oncol, 2005;27(4):981-8).

Additional information can be obtained by contacting Y. Arima, Kurume
University of School...

7/3,K/47 (Item 9 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000372671 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Debiopharm presents new data confirming anti-HCV activity of
cyclophilin inhibitor Debio-025

AIDS Vaccine week, November 27, 2006, p.6

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
378

Debiopharm presents new data confirming anti-HCV activity of
cyclophilin inhibitor Debio-025

...TEXT: specialising in oncology and serious medical conditions,
presented results from a phase Ib study of cyclophilin inhibitor
Debio-025, in treatment-naïve HIV/HCV (hepatitis C virus) co-infected
patients.

The...
... even became undetectable after 8 or 15 days. All three HCV
genotypes (1, 3 and 4) identified in the study, responded well to
the dose administered and no patient developed a...

...Poland and lead investigator of the study.
Debio-025 is a synthetic first-in-class cyclophilin inhibitor
being tested in humans as a potential anti-HCV drug. Debio-025 binds
strongly...

...on the HCV replication was shown in preclinical studies.
This article was prepared by AIDS Vaccine week editors from
staff and other reports. Copyright 2006, AIDS Vaccine week via
NewsRx.com & NewsRx.net.

7/3,K/48 (Item 10 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000370577 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Untitled
Research conducted from Kurume University, Japan, has provided new
information about cancer treatment

Cancer Vaccine Week, November 27, 2006, p.19

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1034

... University, Immunology Center.

The researchers concluded: "Based on these experiences, we propose a
personalized peptide vaccine combined with chemotherapy as a new
treatment modality for cancers."

Itoh and colleagues published their...

...COE Program for Medical Science, Kurume, Fukuoka, Japan.

Study 2: Nonmutated self-antigen-derived cancer vaccine
peptides elicit an IgE-independent, but mast cell-dependent, immediate-type
skin reaction without systemic...

...According to researchers in Japan, "we previously reported an unexpected
phenomenon, i.e., several cancer vaccine peptides, including a
cyclophilin B-derived peptide (CypB-84), elicited an immediate-type
skin reaction in prevaccination skin tests...

...vivo degradation," the authors noted.

They concluded, "These results suggest that certain peptides of cancer
vaccine candidates exhibit an IgE-independent but mast
cell-dependent inflammatory response with no elicitation of...

...and associates published their study in the Journal of Immunology
(Nonmutated self-antigen-derived cancer vaccine peptides elicit an
IgE-independent but mast cell-dependent immediate-type skin reaction
without systemic...

...857-863).

For additional information, contact Akira Yamada, Research Center for
Innovative Cancer Therapy, Cancer Vaccine Development Division, and
Center of the 21st Century Center of Excellence Program for Medical Science
...

...in specific immunotherapy for a wide variety of tumor types. Int J
Oncol, 2005;27(4):981-8).

Additional information can be obtained by contacting Y. Arima, Kurume
University of School...

...Blood, Renal Cancer, Renal Carcinoma, Tumors, Women's Health.

This article was prepared by Cancer Vaccine Week editors from
staff and other reports. Copyright 2006, Cancer Vaccine Week via
NewsRX.com & NewsRX.net.

Untitled

0000349898 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers from Harvard University, U.S., publish new studies and findings in the area of HIV/AIDS

Pharma Business Week, October 30, 2006, p.558

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1042

... TRIMS', mutants lacking arginine 332 to bind HIV-1 capsid complexes. A change in the cyclophilin A-binding loop of the HIV-1 capsid decreased TRIM5 alpha(hu).

"R332P binding and...

...United States, "The induction of both cellular and humoral immunity is an important goal for vaccine development against HIV. As a step towards the development of an efficacious vaccine against HIV clade C, the world's most prevalent strain, a combination DNA prime/protein...

...in (DNA prime/protein boost immunization against HIV clade C: Safety and immunogenicity in mice. Vaccine, 2006;24(13):2324-2332).

For additional information, contact Ruth M. Ruprecht, Department of Cancer...

...for the antiretroviral regimen analysis. QoL domain scores were assessed for subjects 6 months to 4 years, 5 to 11 years, and 12 to 21 years of age, and the impact...

...associated with significantly worse mean adjusted scores for functional status among children 6 months to 4 years of age and health perceptions, physical resilience, physical functioning, and social/role functioning among...

...otherwise, no significant differences were found."

"Generally parents of HIV-infected children 6 months to 4 years and 5 to 11 years of age generally reported lower mean QoL scores than...

DESCRIPTORS: AIDS; AIDS; AIDS Vaccine; Boston; Cancer Vaccine; DNA Research; DNA Vaccine; HAART; HIV; HIV/AIDS; Immunization; Massachusetts; Mental Health; Oncology; Pediatrics; Quality of Life; United States...

7/3,K/50 (Item 12 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000341269 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Studies from the United States and United Kingdom describe new findings in HIV/AIDS research

AIDS Vaccine week, October 9, 2006, p.110

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
886

... Pharmacy, Dept. of Pharmaceutical Science, 1985 Zonal Avenue, Los Angeles, CA 90089, USA.

Study 2: Cyclophilin A alters HIV-1 sensitivity to a TRIM5 alpha-independent innate immune pathway.

"TRIM5 alpha...

...species-specific retroviral replication. Here we investigate the role of the peptidyl prolyl isomerase cyclophilin A in TRIM5 alpha antiviral activity.

"Cyclophilin A is recruited into nascent human immunodeficiency virus type 1 (HIV-1) virions as well...

...exposed proline residue," wrote investigators in England.

According to the authors, "Here we show that cyclophilin A renders HIV-1 sensitive to restriction by TRIM5 alpha in cells from old world monkeys, African green monkey and rhesus macaque. Inhibition of cyclophilin A activity with cyclosporine A, or reducing cyclophilin A expression with small interfering RNA, rescues TRIM5 alpha-restricted HIV-1 infectivity.

"The effect...

...to restrict HIV-1 in a cyclosporine A-sensitive way."

"We use all HIV-1 cyclophilin A binding mutant (CA G89V) to show that cyclophilin A has different roles in restriction by Old world monkey TRIM5 alpha and owl monkey...

...TRIM-Cyp, but not TRIM5 alpha, recruits its tripartite motif to HIV-1 capsid via cyclophilin A and, therefore, HIV-1 G89V is insensitive to TRIM-Cyp but sensitive to TRIM...

...alpha," wrote Z. Keckesova and colleagues at University College London.

Keckesova concluded, "We propose that cyclophilin A isomerization of a proline residue in the TRIM5 alpha sensitivity determinant of the HIV...

...alpha activity, the effects of cyclosporine A are independent of TRIM5 alpha. We speculate that cyclophilin A alters HIV-1 sensitivity to a TRIM5 alpha-independent innate immune pathway in human cells."

Keckesova and colleagues published their study in the (Cyclophilin A renders human immunodeficiency virus type 1 sensitive to old world monkey but not human...

...infected rhesus macaques."

Guare and colleagues published their study in (A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors. Bioorg Med Chem...

...HIV/AIDS, Integrase Inhibitor, Rhesus Macaque, Pharmacokinetics, Viral Replication.

Untitled

This article was prepared by AIDS Vaccine Week editors from staff and other reports. Copyright 2006, AIDS Vaccine Week via NewsRx.com & NewsRx.net.

7/3,K/51 (Item 13 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000327749 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Recent studies from France and the United States add new data to HIV/AIDS research

AIDS Vaccine week, August 21, 2006, p.88

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1113

... equal or superior to biological test cut-offs (BCO) in 14 of the 35 strains, 4 strains had decreased in vitro susceptibility to more than one drug. However, it is important...

...Dept. Molecular Virology & Microbiology, 1 Baylor Pl, Rm 917D, Houston, TX 77030, USA.

Study 3: Cyclophilin A and TRIM5 alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells.

"Cyclophilin A (CypA), a cytoplasmic, human immunodeficiency virus type 1 (HIV-1) CA-binding protein, acts after virion ...

...with human cells to increase HIV-1 infectivity. HIV-1 CA is similarly greeted by CypA soon after entry into rhesus macaque or African green monkey cells, where, paradoxically, the interaction...

...a model in which CA recognition by the human TRIM5 alpha orthologue is precluded by CypA," noted scientists in the United States.

"Consistent with the model, selection of a human cell...

...tropic murine leukemia virus (N-MLV) rendered HIV-1 transduction of these cells independent of CypA," stated Elena Sokolskaja and colleagues at Columbia University. "Additionally, HIV-1 virus-like particles (VLPs) saturate N-MLV restriction activity, particularly when the CA-CypA interaction is disrupted. [In our study] the effects of CypA and TRIM5 alpha on HIV-1 restriction were examined directly."

The researchers reported, "RNA interference... but the magnitude of this antiviral activity was not altered by disruption of the CA-CypA interaction or by elimination of CypA protein. Conversely, the stimulatory effect of CypA on HIV-1 infectivity was completely independent of human TRIM5 alpha."

"Together with previous reports, these data suggest that CypA protects HIV-1 from an unknown antiviral activity in human cells," the authors concluded. "Additionally...

...with a common saturable target that is epistatic to both TRIM5 alpha and
Page 38

the putative CypA-regulated restriction factor."
Sokolskaja and associates published their study in the Journal of virology (Cyclophilin A and TRIM5 alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells...

...10032, USA. j145@columbia.edu.

Keywords: New York, New York, United States, AIDS and HIV Vaccine, Vaccine Development, Antiviral Activity, Immunology, Immunotherapy, Human Immunodeficiency Virus, Virology, Proteomics.

This article was prepared by AIDS Vaccine Week editors from staff and other reports. Copyright 2006, AIDS Vaccine Week via NewsRx.com & NewsRx.net.

DESCRIPTORS: AIDS; AIDS; AIDS Vacc; AIDS and HIV Vaccine; Antiviral Activity; Drug Resistance; HIV; HIV/AIDS; Human Immunodeficiency Virus; Immunology; Immunotherapy; New York; Proteomics; Therapy; Treatment; United States; Vaccine Development; Virology; All News; Professional News

7/3,K/52 (Item 14 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000325807 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers from the United States and South Korea report recent findings in HIV/AIDS

AIDS Vaccine Week, August 14, 2006, p.87

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1071

... Israel Deaconess Medical Center, Division Experimental Med, Center Med, Harvard Institute Med Bldg, Rm 343, 4 Blackfan Circle, Boston, MA 02115, USA.

Study 2: Cyclophilin A and TRIM5 alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells.

"Cyclophilin A (CypA), a cytoplasmic, human immunodeficiency virus type 1 (HIV-1) CA-binding protein, acts after virion ...

...with human cells to increase HIV-1 infectivity. HIV-1 CA is similarly greeted by CypA soon after entry into rhesus macaque or African green monkey cells, where, paradoxically, the interaction...

...a model in which CA recognition by the human TRIM5 alpha orthologue is precluded by CypA," noted scientists in the United States.

"Consistent with the model, selection of a human cell...

...tropic murine leukemia virus (N-MLV) rendered HIV-1 transduction of

Untitled
these cells independent of CypA," stated Elena Sokolskaja and colleagues at Columbia University. "Additionally, HIV-1 virus-like particles (VLPs) saturate N-MLV restriction activity, particularly when the CA-CypA interaction is disrupted. [In our study] the effects of CypA and TRIM5 alpha on HIV-1 restriction were examined directly." The researchers reported, "RNA interference..."

...but the magnitude of this antiviral activity was not altered by disruption of the CA-CypA interaction or by elimination of CypA protein. Conversely, the stimulatory effect of CypA on HIV-1 infectivity was completely independent of human TRIM5 alpha."

"Together with previous reports, these data suggest that CypA protects HIV-1 from an unknown antiviral activity in human cells," the authors concluded. "Additionally..."

...with a common saturable target that is epistatic to both TRIM5 alpha and the putative CypA-regulated restriction factor."

Sokolskaja and associates published their study in the Journal of Virology (Cyclophilin A and TRIM5 alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells..."

...AIDS, HIV Vpr Protein, Apoptosis, Bystander Cells, Viral Pathogenesis.

This article was prepared by AIDS Vaccine Week editors from staff and other reports. Copyright 2006, AIDS Vaccine Week via NewsRx.com & NewsRx.net.

7/3,K/53 (Item 15 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000310332 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers' data from the United States and India advance HIV/AIDS research

AIDS Vaccine Week, June 19, 2006, p.63

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1186

... restriction of HIV-1 infection.

"We sequenced the TRIM5 gene (excluding exon 5) and the 4.8-kb 5' putative regulatory region in genomic DNA from 110 HIV-1-infected subjects..."

...N, D3-100, Seattle, WA 98109, USA.

Study 2: Study finds that the effect of CypA on HIV-1 replicative ability is bimodal and both high and low CypA content limits HIV-1 replication.

"HIV-1 Gag protein interaction with cyclophilin A (CypA) is critical for viral fitness. Among the amino acid substitutions identified in Gag noncleavage sites..."

...et al., (2002) J. Biol. Chem. 277, 5952-5961) and H219P substitutions in
Page 40

Untitled
the viral CypA binding loop confer the greatest replication advantage to HIV-1. These substitutions represent polymorphic amino...

...National Cancer Institute determined "the replication advantage conferred by these substitutions was far greater in CypA-rich MT-2 and H9 cells than in Jurkat cells and peripheral blood mononuclear cells (PBM), both of which contained less CypA. High intracellular CypA content in H9 and MT-2 cells, resulting in excessive CypA levels in virions, limited wild-type HIV-1 (HIV-1 WT) replication and H219Q introduction into HIV-1 (HIV-1 H219Q), reduced CypA incorporation of HIV-1, and potentiated viral replication."

They continued, "H219Q introduction also restored the otherwise compromised replication of HIV-1 P222A in PBM, although the CypA content in HIV-1 H219Q/P222A was comparable with that in HIV-1 P222A, suggesting that H219Q affected the conformation of the CypA-binding motif, rendering HIV-1 replicative in a low CypA environment."

"Structural modeling analyses revealed that although hydrogen bonds are lost with H219Q and H219P substitutions, no significant distortion of the CypA binding loop of Gag occurred. The loop conformation of HIV-1 P222A was found highly...

...that of HIV-1WT."

The researchers concluded, "The present data suggested that the effect of CypA on HIV-1 replicative ability is bimodal (both high and low CypA content limits HIV-1 replication), that the conformation of the CypA binding region of Gag is important for viral fitness, and that the function of CypA is to maintain the conformation."

Gatanaga and colleagues published their study in the Journal of Biological Chemistry (Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop. J Biol Chem, 2006;281(2):1241-1250).

Additional information can be obtained...

...40, HIV-1 Nef, Gene Expression & Replication, Viral Pathogenesis.

This article was prepared by AIDS Vaccine week editors from staff and other reports. Copyright 2006, AIDS Vaccine week via NewsRx.com & NewsRx.net.

7/3,K/54 (Item 16 from file: 135) Links
NewsRx Weekly Reports
(C) 2008 NewsRx. All rights reserved.

0000272266 (USE FORMAT 7 OR 9 FOR FULLTEXT)

New findings in the area of HIV/AIDS vaccines detailed

AIDS Vaccine week, January 23, 2006, p.26

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
907

...TEXT: and fowlpox virus-based recombinant vaccines reduce acute phase
Page 41

Untitled
viral replication in macaques following vaginal challenge with
CCR5-tropic SHIV.

... macaques," scientists in Australia report.
"Some protection from acute infection with a pathogenic vaginal SHIV
challenge was, however, observed with a regimen involving
intramuscular DNA vaccine priming followed by either intranasally or
intrarectally delivered rFPV boosting," said Stephen J. Kent at the
University of Melbourne and collaborators in Australia. "Interestingly,
animals boosted with rFPV vaccine via either of these mucosal routes
had poor circulating T cell responses prior to challenge with SHIV
compared to those boosted via the intramuscular route."
"Nevertheless, the mucosally-vaccinated animals...

...cell responses following SHIV administration, with significant reduction
in acute plasma viremia against this vaginal challenge," reported
Kent and his colleagues. "Our data suggest strategies for effective priming
of partial immunity...

...systemic prime and mucosal boost vaccination strategies."

Kent and his coauthors published their study in Vaccine
(Mucosally-administered human-simian immunodeficiency virus DNA and
fowlpoxvirus-based recombinant vaccines reduce acute phase viral
replication in macaques following vaginal challenge with CCR5-tropic
SHIV. Vaccine, 2005;23(42):5009-5021).

For additional information, contact Stephen J. Kent, Department of
Microbiology...

...the determinant for TRIM5 alpha sensitivity to the structure in the
capsid protein that recruits CypA into HIV-1 virions."

"We also make an SIV, mutated at this site, which bypasses...

...Study 3: Standardization of nonhuman primate models is necessary for
assessing the efficacy of AIDS vaccine strategies prior to phase 3
clinical trials.

According to a review from Germany, "Since only...

...the predictive value of these models, comparative efficacy studies in
NHPS could facilitate ranking of vaccine candidates."

"While various forms of protein vaccines failed to induce consistent
protection, live-attenuated vaccines...

...urgent necessity in order to exploit the full potential of nonhuman
primate models in AIDS vaccine development."

Uberla published the review in Medical Microbiology and Immunology
(Efficacy of AIDS vaccine strategies in nonhuman primates. Med
Microbiol Immunol (Berl), 2005;194(4):201-206).

For more information, contact Klaus Uberla, Department of Molecular
and Medical Virology, Ruhr...

...44780 Bochum, Germany. klaus.ueberla@ruhr-uni-bochum.de.

Keywords: Bochum, Germany, AIDS and HIV Vaccine, Vaccine
Development, Vaccine Efficacy, DNA Vaccine, Immunology,
Immunotherapy, Animal Models, Human Immunodeficiency Virus, Virology.

This article was prepared by AIDS Vaccine Week editors from
staff and other reports. Copyright 2006, AIDS Vaccine Week via
NewsRx.com & NewsRx.net.

DESCRIPTORS: AIDS; AIDS and HIV Vaccine; Animal Models; Bochum
; DNA Vaccine; Drug Development; Germany; HIV;
HIV/AIDS Vaccines; Human Immunodeficiency Virus;
Immunology; Immunotherapy; Pharmaceuticals; Therapy;
Treatmen; Vaccine Development; Vaccine
Efficacy; Virology; All News

Untitled

7/3,K/55 (Item 17 from file: 135) Links
NewsRx Weekly Reports
(C) 2008 NewsRx. All rights reserved.

0000263458 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Reports advance knowledge in HIV/AIDS vaccines research

AIDS Vaccine week, December 12, 2005, p.17

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
943

... the determinant for TRIM5 alpha sensitivity to the structure in the capsid protein that recruits CypA into HIV-1 virions."
"We also make an SIV, mutated at this site, which bypasses...

...unmatched mononuclear cells would induce systemic alloimmune responses. Rectal or vaginal mucosal administration of 10 4 -10 7 unmatched mononuclear cells induced significant dose-dependent T-cell proliferation stimulated by the...

...study of the T cell immunity induced by these vaccines prior to and following SHIV challenge utilizing intracellular cytokine staining."
"Pigtail macaques vaccinated intramuscularly with DNA/recombinant fowlpox virus exhibited a...

...of Melbourne. "Overall, the magnitude and timing of the peak CD8 T cell responses following challenge was significantly associated with reductions in SHIV viremia following pathogenic challenge."

"After pathogenic lentiviral challenge, virus-specific effector memory T cells derived from animals controlling SHIV infection recognized a broad...

...Parkville, Victoria 3010, Australia. skent@unimelb.edu.au.

Keywords: Parkville, Victoria, Australia, AIDS and HIV Vaccine, Vaccine Development, Vaccine Efficacy, DNA Vaccine, Immunology, Immunotherapy, Proteomics, Recombinant Technology, Human Immunodeficiency Virus, Virology.

This article was prepared by AIDS Vaccine week editors from staff and other reports. Copyright 2005, AIDS Vaccine week via NewsRx.com & NewsRx.net.

DESCRIPTORS: AIDS; AIDS; AIDS and HIV Vaccine; Australia; DNA Vaccine; HIV; HIV/AIDS Vaccines; Human Immunodeficiency Virus; Immunology; Immunotherapy; Parkville; Proteomics; Recombinant Technology; Vaccine Development; Vaccine Efficacy; Victoria; Virology; All News; Professional News

Untitled

7/3,K/56 (Item 18 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000260661 (USE FORMAT 7 OR 9 FOR FULLTEXT)

New findings in the area of proteomics described

Life Science Weekly, November 29, 2005, p.469

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
936

... fold depending on the ambient pH. At pH 5.5, the dfc-14 and hfm-4 mutants had an abnormal hyphal morphology that is consistent with fragmentation of vacuoles and defects...

...In contrast," they added, "the hyphal and vacuolar morphology of the dfc-14 and hfm-4 mutants was normal at pH 8.0, although CPY-EGFP accumulated in perivacuolar dot-like...

...the target cells and its 5' flanking untranslated region. Biochem Biophys Res Commun, 2005;330(4):1275-1284).

For more information, contact Jian-Gang Zhang, Diagnostic and Molecular Medicine Healthcare Group...

...proteins: green fluorescent protein, ferredoxin:NADP oxidoreductase, NADPH:thioredoxin reductase, thioredoxin f, fructose bisphosphatase, and cyclophilin."

"Individual IgGs were re-purified from the serum through specific interaction on small columns generated...

...comes under the major subject areas of Proteomics, Affinity Chromatography, Polyclonal Antibodies, Immunology, Immunotherapy, and Vaccine Development.

This article was prepared by Life Science Weekly editors from staff and other reports...

...DESCRIPTORS: Development; Genetics; Genomics; Immunology; Immunotherapy; Pharmaceuticals; Polyclonal Antibodies; Proteomics; Therapy; Treatment; University of Tokyo; and Vaccine Development; All News; Professional News

7/3,K/57 (Item 19 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000258734 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers describe findings in HIV/AIDS therapy studies

Untitled

AIDS Vaccine week, November 21, 2005, p.38

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1089

...TEXT: N-terminal region plays a critical role in HIV-1 inhibition by Toxoplasma gondii -derived cyclophilin-18.
... mimicry of chemokine ligands has been described for several pathogens. Toxoplasma gondii produces a protein, cyclophilin-18 (C-18), which binds to the human immunodeficiency virus (HIV) co-receptor CCR5 and...

...N-terminal region plays a critical role in HIV-1 inhibition by Toxoplasma gondii -derived cyclophilin-18. J Biol Chem, 2005;280(33):29570-29577).

For additional information, contact Hana Golding...

...TEFb kinase activity is critical for the induction of methylation of histone H3 at lysine 4 and lysine 36 on HIV-1 genes."

The authors concluded, "Flavopiridol, a potent P-TEFb...

...TEFb Kinase Inhibitor, Genomics & Genetics and Pharmaceutical & Drug Development.

This article was prepared by AIDS Vaccine week editors from staff and other reports. Copyright 2005, AIDS Vaccine week via NewsRX.com & NewsRX.net.

7/3,K/58 (Item 20 from file: 135) Links
NewsRX weekly Reports
(c) 2008 NewsRX. All rights reserved.

0000242425 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers detail new studies and findings in the area of HIV/AIDS pathogenesis

AIDS vaccine week, September 12, 2005, p.13

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1051

... Med, 2005;201(12):2023-2033).
For additional information, contact K. Lore, NIAID, Immunology Laboratory, Vaccine Research Center, NIH, Bldg 10, Bethesda, MD 20892, USA.

Untitled

Study 2: HIV-1-induced macrophage...

...Dr., Bldg 30, Rm 332, MSC 4352, Bethesda, MD 20892, USA.

Study 3: Target cell Cyclophilin A modulates HIV-1 infectivity.

"The peptidyl-prolyl isomerase cyclophilin A (CypA) increases the kinetics by which human immunodeficiency virus type 1 (HIV-1) spreads in tissue...

...was conclusively demonstrated by gene targeting in human CD4+ T cells, but the role of CypA in HIV-1 replication remains unknown.

"Though CypA binds to mature HIV-1 capsid protein (CA), it is also incorporated into nascent HIV...

...interaction with the CA domain of the Gag polyprotein. These findings raised the possibility that CypA might act at multiple steps of the retroviral life cycle."

"Disruption of the CA-CypA interaction, either by the competitive inhibitor cyclosporine (CsA) or by mutation of CA residue G89 or P90, suggested that producer cell CypA was required for full virion infectivity.

"However," wrote E. Sokolskaja and colleagues, "recent studies indicate that CypA within the target cell regulates HIV-1 infectivity by modulating Ref1- or Lvl-mediated restriction."

"To examine the relative contribution to HIV-1 replication of producer cell CypA and target cell CypA," said the authors, "we exploited multiple tools that disrupt the HIV-1 CA-CypA interaction."

"These tools included the drugs CsA, Melle (4)-CsA, and Sanglifehrin; CA mutants exhibiting decreased affinity for CypA or altered CypA dependence; HeLa cells with CypA knockdown by RNA interference; and Jurkat T cells homozygous for a deletion of the gene encoding CypA."

"Our results clearly demonstrate that target cell CypA, and not producer cell CypA, is important for HIV-1 CA-mediated function. Inhibition of HIV-1 infectivity resulting from virion production in the presence of CsA occurs independently of the CA-CypA interaction or even of CypA," concluded Sokolskaja.

Sokolskaja and colleagues published their study in the Journal of Virology (Target cell Cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol, 2004;78(23):12800-12808...

...information in this article comes under the major subject areas of HIV/AIDS, Genomics & Genetics, Cyclophilin A and HIV Pathogenesis.

This article was prepared by AIDS Vaccine Week editors from staff and other reports. Copyright 2005, AIDS Vaccine Week via NewsRx.com & NewsRx.net.

DESCRIPTORS: AIDS; AIDS Vaccine; Cyclophilin A and HIV Pathogenesis; Disease Association; Genetics; Genomics; Genomics & Genetics; HIV; HIV/AIDS; HIV/AIDS...

7/3,K/59 (Item 21 from file: 135) Links

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

0000231297 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers' findings advance HIV/AIDS pathogenesis research

Untitled

AIDS Vaccine week, July 25, 2005, p.12

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1103

... blood and mucosa," investigators said, "with Nef being the most highly targeted (mean of 2.4 spot-forming cells (SFC)/10⁶ CD8+ T lymphocytes/amino acid [SFC/CD8/aa]), followed...

...derived from the N ten-ninus of HIV-1 PR inhibits Vif/PR binding; and (4) this peptide inhibits the propagation of HIV-1 in restrictive cells."

"Based on these data...

...Hadassah Medical School, Department Pathology, POB 12000, IL-91120 Jerusalem, Israel.

Study 3: Target cell Cyclophilin A modulates HIV-1 infectivity.

"The peptidyl-prolyl isomerase cyclophilin A (CypA) increases the kinetics by which human immunodeficiency virus type 1 (HIV-1) spreads in tissue...

...was conclusively demonstrated by gene targeting in human CD4+ T cells, but the role of CypA in HIV-1 replication remains unknown.

"Though CypA binds to mature HIV-1 capsid protein (CA), it is also incorporated into nascent HIV...

...interaction with the CA domain of the Gag polyprotein. These findings raised the possibility that CypA might act at multiple steps of the retroviral life cycle."

"Disruption of the CA-CypA interaction, either by the competitive inhibitor cyclosporine (CsA) or by mutation of CA residue G89 or P90, suggested that producer cell CypA was required for full virion infectivity.

"However," wrote E. Sokolskaja and colleagues, "recent studies indicate that CypA within the target cell regulates HIV-1 infectivity by modulating Rfl- or Lvl-mediated restriction."

"To examine the relative contribution to HIV-1 replication of producer cell CypA and target cell CypA," said the authors, "we exploited multiple tools that disrupt the HIV-1 CA-CypA interaction."

"These tools included the drugs CsA, Melle (4)-CsA, and Sanglifehrins; CA mutants exhibiting decreased affinity for CypA or altered CypA dependence; HeLa cells with CypA knockdown by RNA interference; and Jurkat T cells homozygous for a deletion of the gene encoding CypA."

"Our results clearly demonstrate that target cell CypA, and not producer cell CypA, is important for HIV-1 CA-mediated function. Inhibition of HIV-1 infectivity resulting from virion production in the presence of CA occurs independently of the CA-CypA interaction or even of CypA," concluded Sokolskaja.

Sokolskaja and colleagues published their study in the Journal of Virology (Target cell Cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol, 2004;78(23):12800-12808...

...information in this article comes under the major subject areas of HIV/AIDS, Genomics & Genetics, Cyclophilin A and HIV

Untitled

Pathogenesis.

This article was prepared by AIDS Vaccine week editors from staff and other reports. Copyright 2005, AIDS Vaccine week via NewsRx.com & NewsRx.net.

DESCRIPTORS: AIDS; Cyclophilin A and HIV Pathogenesis; Disease Association; Genetics; Genomics; Genomics & Genetics ; HIV; HIV/AIDS; HIV/AIDS...

7/3,K/60 (Item 22 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000190916 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Target cell Cyclophilin A modulates HIV-1 infectivity

AIDS Vaccine week, February 7, 2005, p.20

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
404

Target cell Cyclophilin A modulates HIV-1 infectivity

TEXT: Target cell Cyclophilin A modulates HIV-1 infectivity.
"The peptidyl-prolyl isomerase cyclophilin A (CypA) increases the kinetics by which human immunodeficiency virus type 1 (HIV-1) spreads in tissue...

...was conclusively demonstrated by gene targeting in human CD4+ T cells, but the role of CypA in HIV-1 replication remains unknown.

"Though CypA binds to mature HIV-1 capsid protein (CA), it is also incorporated into nascent HIV...

...interaction with the CA domain of the Gag polyprotein. These findings raised the possibility that CypA might act at multiple steps of the retroviral life cycle."

"Disruption of the CA-CypA interaction, either by the competitive inhibitor cyclosporine (CsA) or by mutation of CA residue G89 or P90, suggested that producer cell CypA was required for full virion infectivity.

"However," wrote E. Sokolskaja and colleagues, "recent studies indicate that CypA within the target cell regulates HIV-1 infectivity by modulating Ref1- or Lvl-mediated restriction."

"To examine the relative contribution to HIV-1 replication of producer cell CypA and target cell CypA," said the authors, "we exploited multiple tools that disrupt the HIV-1 CA-CypA interaction."

"These tools included the drugs CsA, Melle (4)-CsA, and Sangliferrin; CA mutants exhibiting decreased affinity for CypA or altered CypA dependence; HeLa cells with CypA knockdown by RNA interference; and Jurkat T cells homozygous for a deletion of the gene encoding CypA."

Untitled

"Our results clearly demonstrate that target cell CypA, and not producer cell CypA, is important for HIV-1 CA-mediated function. Inhibition of HIV-1 infectivity resulting from virion production in the presence of CSA occurs independently of the CA-CypA interaction or even of CypA," concluded Sokolskaja.

Sokolskaja and colleagues published their study in the Journal of Virology (target cell Cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol, 2004;78(23):12800-12808...

...information in this article comes under the major subject areas of HIV/AIDS, Genomics & Genetics, Cyclophilin A and HIV Pathogenesis.

This article was prepared by AIDS Vaccine Week editors from staff and other reports. Copyright 2005, AIDS Vaccine Week via NewsRx.com & NewsRx.net.

7/3,K/61 (Item 23 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000169644 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Antisense U7 snRNAs and siRNAs targeting cyclophilin A inhibit HIV-1 replication

AIDS Vaccine Week, November 1, 2004, p.20

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
338

Antisense U7 snRNAs and siRNAs targeting cyclophilin A inhibit HIV-1 replication

TEXT: Antisense U7 snRNAs and siRNAs targeting cyclophilin A inhibit HIV-1 replication.

According to published research from Switzerland, "Human immunodeficiency virus 1 (HIV-1) multiplication depends on a cellular protein, cyclophilin A (CyPA), that gets integrated into viral particles. Because CyPA is not required for cell viability, we attempted to block its synthesis in order to...

"For this purpose, we used antisense U7 small nuclear RNAs (snRNAs) that disturb CyPA pre-mRNA splicing and short interfering RNAs (siRNAs) that target CyPA mRNA for degradation," wrote S.K. Liu and coworkers.

"With dual-specificity U7 snRNAs targeting the 3' and 5' splice sites of CyPA exons 3 or 4," investigators reported, "we obtained an efficient skipping of these exons and a strong reduction of CyPA protein. Furthermore, short interfering RNAs targeting two segments of the CyPA coding region strongly reduced CyPA mRNA and protein levels."

"Upon lentiviral vector-mediated transduction, prolonged antisense effects were obtained for...

Untitled

...Nucleic Acids Research (Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A. Nucleic Acids Res, 2004;32(12):3752-3759).

Additional information can be obtained by contacting D. Schumperli, University Bern, Institute Cell Biology, Baltzerstr 4, CH-3012 Bern, Switzerland.

The publisher of the journal Nucleic Acids Research can be contacted

...

...subject areas of HIV/AIDS, Genomics & Genetics, and Proteomics.

This article was prepared by AIDS Vaccine Week editors from staff and other reports. Copyright 2004, AIDS Vaccine Week via NewsRx.com & NewsRx.net.

7/3,K/62 (Item 1 from file: 357) Links

Derwent Biotech Res.

(c) 2008 The Thomson Corp. All rights reserved.

0421833 DBA Accession No.: 2007-07771 PATENT

New fusion protein comprising a stress protein, useful for inducing an immune response against an antigen of an influenza virus involving plasmid pET65MP/NP-B or plasmid pET65MP/NP-D vector-mediated gene expression, useful for vaccine production

Author: MIZZEN L; ANTHONY L S D; WU H B; SIEGEL M

Patent Assignee: STRESSGEN BIOTECHNOLOGIES CORP 2007

Patent Number: US 7157089 Patent Date: 20070102 WPI Accession No.: 2007-204591 (200721)

Priority Application Number: US 977787 Application Date: 19971125

National Application Number: US 977787 Application Date: 19971125

Language: English

...plasmid pET65MP/NP-B or plasmid pET65MP/NP-D vector-mediated gene expression, useful for vaccine production

Abstract: ...the KFBP is FKBP12, FKBP13, FKBP25, FKBP59, Fpr1, or Nep1. The stress protein is a cyclophilin, where the cyclophilin is cyclophilin A, cyclophilin B, or cyclophilin C. The stress protein is an Hsp20-30, where the Hsp20-30 is a Tcp1...
...to enhance the aqueous solubility of the P1Anonamer. Restimulated effector cells were then cultured for 4-5 hours with 51Cr-labelled target cells. Targets were cells of the PLA antigen-expressing... ..maximal response seen in cells from mice immunized with 50-500 micrograms. MECHANISM OF ACTION - Vaccine. USE - The fusion protein, composition, vaccine, and method are useful for inducing an immune response against an antigen of an influenza...

E.C. Numbers:

Descriptors: ...pET65MP/NP-B, plasmid pET65MP/NP-D, cytotoxic T-lymphocyte, excipient, carrier, diluent, vehicle, appl., vaccine immunostimulant protein bacterium protein sequence virus orthomyxo virus enzyme EC-3.2.1.18 EC-5.3. 4.1 (26, 15)

7/3,K/63 (Item 2 from file: 357) Links

Derwent Biotech Res.

(c) 2008 The Thomson Corp. All rights reserved.

0408286 DBA Accession No.: 2006-21782 PATENT

Transgenic non-human animal cell for treating e.g. disease caused by excess granzyme B activity, and for increasing immunity to viral infection, comprises disrupted serine protease inhibitor gene involving vector-mediated disrupted serine protease-inhibitor-6 protein serpine transgene transfer and expression in host cell

Author: ASHTON-RICKARDT P G; ZHANG M

Patent Assignee: UNIV CHICAGO 2006

Patent Number: WO 200691773 Patent Date: 20060831 WPI Accession No.: 2006-595219

Untitled

(200661)

Priority Application Number: US 656492 Application Date: 20050225

National Application Number: WO 2006US6524 Application Date: 20060224

Language: English

Abstract: ...CD8+) memory T cells, by inhibiting programmed cell death, comprising administering a vector expressing Spi6; (4) a method of identifying a candidate inhibitor of Spi6/proteinase inhibitor 9 (Spi6/PI9) activity... ..B activity by inhibiting Granzyme B, comprising administering a composition that expresses Spi6; (9) a vaccine which decreases the number of boosters required to obtain memory cells comprising Spi6 or PI9preferably 90%) identity to Spi6 protein having sequence of 374 amino acids (SEQ ID NO:4) given in the specification. The PI9 comprises a sequence having greater than or equal to 90%mouse mast cell protein (MMCP-1) -1 (P11034), MMCP-2 (P15119), MMCP-3 (P21843), MMCP-4 (P21812), MMCP-5 (P21844), MMCP-8 (P43430), MMCP-9 (O35164), MMCP-10 (AAK51075), or caspase... ..19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2, fold, over the amount of the serpin expressed in the naive cells of an animal not having the transgene. The ratio of serpin to cyclophilin is at least 100, 75, 53, 50, 40, 31.6, 30, 29, 28, 27, 26... ..19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2. The animal not expressing the transgene is a B6 mouse. The expression... ..cells. The cell culture comprises a neutrophil or macrophage from a Spi6 transgenic mouse. The vaccine further comprises an adjuvant. Preferred Method: The animal was produced by introducing into a non... ..inhibitor of Spi6. ACTIVITY - Virucide; Antiinflammatory; Antibacterial. Higher doses of human neutrophil elastase (HNE) (2.4-5.9 U/kg), were detrimental to the survival of B6 mice after infection with... ..E.C. Numbers:

7/3,K/64 (Item 3 from file: 357) Links

Derwent Biotech Res.

(c) 2008 The Thomson Corp. All rights reserved.

0375796 DBA Accession No.: 2005-21502 PATENT

New nucleic acid comprising *Listeria monocytogenes* hly 5' UTR or actA 5' UTR, a ribosome binding site (RBS) and a heterologous nucleic acid sequence, useful in inducing an immune response to a bacterial, fungal, parasitic or cancer antigen bacterium protein production and expression vector for use in vaccine and gene therapy

Author: HIGGINS D E; SHEN A

Patent Assignee: HIGGINS D E; SHEN A 2005

Patent Number: US 20050147621 Patent Date: 20050707 WPI Accession No.: 2005-487940

(200549)

Priority Application Number: US 961291 Application Date: 20041008

National Application Number: US 961291 Application Date: 20041008

Language: English

...bacterial, fungal, parasitic or cancer antigen bacterium protein production and expression vector for use in vaccine and gene therapy

Abstract: ...a bacterium comprising a nucleic acid comprising the same components as the vector of (2); (4) a vaccine comprising the bacterium; (5) a vaccine comprising the isolated nucleic acid (1); (6) introducing an antigen into a eukaryotic cell comprising... ..707 alanine proline (707-AP); alpha ((x))-fetoprotein (AFP); adenocarcinoma antigen recognized by T cells 4 (ART-4); B antigen (BAGE); beta-catenin/mutated(b-catenin/m); breakpoint cluster region-Abelson (Bcr-abl... ..CAP-1); caspase-8 (CASP-8); cell-division cycle 27 mutated (CDC27m); cyclin-dependent kinase 4 mutated CDK4/m); carcinoembryonic antigen (CEA); cancer/testis (CT) antigen; cyclophilin B (Cyp-B); differentiation antigen melanoma (DAM-6, also known as MAGEB2, and DAM-10lactis bacterium.ACTIVITY - Antiviral; Antibacterial; Fungicide; Antiparasitic; Cytostatic. No biological data given. MECHANISM OF ACTION - Vaccine; Gene therapy. USE - The nucleic acid and the bacterium containing the nucleic acid are useful...

E.C. Numbers:

Descriptors: ...bacterium replication origin, appl. virus, bacterium, fungus, parasite infection, cancer therapy, RNA inhibition, nucleic acid vaccine, gene therapy bacterium virucide fungicide cytostatic (24, 34)

Untitled

7/3,K/65 (Item 4 from file: 357) Links

Derwent Biotech Res.

(c) 2008 The Thomson Corp. All rights reserved.

0301841 DBA Accession No.: 2003-03626 PATENT

Novel isolated fusion protein useful for treating hepatitis B virus infection in a subject, comprises a stress protein or its portion, and a hepatitis B virus core antigen retro virus-mediated heat shock protein fusion protein gene transfer and expression in host cell for use in disease gene therapy and recombinant vaccine

Author: MIZZEN L; LIU H; SIEGEL M

Patent Assignee: STRESSGEN BIOTECHNOLOGIES CORP 2002

Patent Number: WO 200262959 Patent Date: 20020815 WPI Accession No.: 2002-706903 (200276)

Priority Application Number: US 266733 Application Date: 20010205

National Application Number: WO 2002US3460 Application Date: 20020205

Language: English

...gene transfer and expression in host cell for use in disease gene therapy and recombinant vaccine

Abstract: ...nucleic acid (III) comprising a sequence that encodes (I); (3) expression vector (IV) comprising (III); (4) retroviral vector (V) comprising (III); (5) cell (VI) comprising (IV); and (6) production of (Iprotein is selected from Hsp10, Hsp40, Hsp60, Hsp70, Hsp90, Hsp100-200, Hsp100, Lon, TF55, FKBP, cyclophilin, Hsp20-30, Clpp, GrpE, ubiquitin, calnexin, protein disulfide isomerase or small molecular weight family of... ..the specification. ACTIVITY - Virucide; Immunostimulant; Hepatotropic; Antiinflammatory.No biological data is given.

MECHANISM OF ACTION - Vaccine; Gene therapy. USE - (I), (II), (IV) or (V) are useful for inducing or enhancing an...

E.C. Numbers:

Descriptors: ...40, Hsp-60, Hsp-70, Hsp-90, Hsp-100-200, Hsp-100, Lon, TF55, FKBP, cyclophilin, Hsp-20-30, Clpp, GrpE, ubiquitin, calnexin, protein disulfide isomerase, Mycobacterium tuberculosis, Mycobacterium bovis BCG... ..gene transfer, expression in host cell, appl. hepatitis B virus infection, cirrhosis gene therapy, recombinant vaccine hepadna virus bacterium DNA sequence protein sequence (22, 07)

7/3,K/66 (Item 5 from file: 357) Links

Derwent Biotech Res.

(c) 2008 The Thomson Corp. All rights reserved.

0300748 DBA Accession No.: 2003-02532 PATENT

Inducing or sustaining immunological cytotoxic T lymphocyte response in a mammal, useful for treating a mammal with malignant tumor or infectious disease, by directly administering an antigen to the lymphatic system of the mammal palnsid-mediated gene transfer and expression in mouse lymphoid tissue for cancer and disease infection nucleic acid vaccine and gene therapy

Author: KUNDIG T M; SIMARD J J L

Patent Assignee: CTL IMMUNOTHERAPIES CORP 2002

Patent Number: WO 200262368 Patent Date: 20020815 WPI Accession No.: 2002-657506 (200270)

Priority Application Number: US 776232 Application Date: 20010202

National Application Number: WO 2002US2033 Application Date: 20020122

Language: English

...gene transfer and expression in mouse lymphoid tissue for cancer and disease infection nucleic acid vaccine and gene therapy

Abstract: ...MG7-Ag, MOV18, NB/70K, NY-CO-1, RCAS1, SDCCAG16, TA-90 (mac-2 binding protein)cyclophilin C-associated protein), TAAL6, TAG72, TLP or TPS. The vector comprises an antigen-encoding nucleic... ..0.5 mM ethylene diamine tetraacetate (EDTA), and a citrate-phosphate buffer of pH 7.4-7.8, comprising about 3-50 mM citrate and about 90-200 mM phosphate. An... ..1% benzyl alcohol, 0.5 mM EDTA, and a citrate-phosphate buffer of pH 7.4-7.8 comprising 50 mM citrate and 100 mM phosphate. ACTIVITY - Cytotoxic; Antibacterial; Virucide; Protozoacide... ..that

Untitled

mice immunized with 200 microg intramuscularly showed only weak anamnestic CTL responses following LCMV challenge. Those immunized via the intrasplenic route showed strong anamnestic CTL response when only 2 microg...

E.C. Numbers:

Descriptors: ...MG7-Ag, MOV18, NB-70K, NY-CO-1, RCAS1, SDCCAG16, TA-90, mac-2 binding protein, cyclophilin C-associated protein, TAAL6, TAG72, TLP, TPS antigen gene transfer, expression in mouse lymphoid tissue... ..human malignant tumor, carcinoma, melanoma, leukemia, lymphoma, hepatitis, AIDS, malaria, measles, tuberculosis infection nucleic acid vaccine, gene therapy mammal animal cancer DNA sequence protein sequence (22, 05)

7/3,K/67 (Item 6 from file: 357) Links

Derwent Biotech Res.

(c) 2008 The Thomson Corp. All rights reserved.

0294138 DBA Accession No.: 2002-15985 PATENT

Novel G protein-coupled receptor, HGPRBM5 polypeptide, useful for treatment of AIDS, allergies, asthma, atherosclerosis, ulcerative colitis, atopic dermatitis, diabetes mellitus, glomerulonephritis, osteoarthritis vector-mediated recombinant protein gene transfer and expression in host cell for disease or disorder prevention, diagnosis and gene therapy

Author: FEDER J N; MINTIER G; RAMANATHAN C S; HAWKEN D R

Patent Assignee: BRISTOL-MYERS SQUIBB CO 2002

Patent Number: WO 200226824 Patent Date: 20020404 WPI Accession No.: 2002-435196 (200246)

Priority Application Number: US 310436 Application Date: 20010803

National Application Number: WO 2001US30365 Application Date: 20010926

Language: English

Abstract: ...polynucleotide which represents the complementary sequence of S3 or S4, a polynucleotide corresponding to nucleotides 4-2211 or 1-2211 of S3, a polynucleotide corresponding to nucleotides 4-2139 or 1-2139 of S4, or a polynucleotide capable of hybridizing under stringent conditions... ..2) a recombinant vector (III) comprising (I); (3) making a recombinant host cell comprising (II); (4) a recombinant host cell (IV) produced by the above said method; (5) an isolated antibody... ..compositions comprising (I); (3) detecting a polynucleotide that encodes HGPRBM5 polypeptide in a biological sample; (4) compositions for diagnosing brain-, ovarian-, thymus-, and lung-related disorders and response to HGPRBM5 therapy... ..polypeptides that intervene between each of the predicted HGPRBM5 transmembrane domain; and (10) immunological or vaccine formulation comprising (I) or (II). BIOTECHNOLOGY - Preparation: (I) is produced by culturing (IV) under conditions... ..Antihelminthic; Nootropic; Neuroprotective; Antidepressant; Anticonvulsant; Antiparkinsonian; Neuroleptic; Anti-HIV. MECHANISM OF ACTION - Modulator of (I); vaccine; gene therapy. No supporting data given. USE - (I) or (II) is useful for preventing, treating...each assay was determined by performing a parallel experiment until a primer pair for the cyclophilin gene, which was expressed in equal amounts in all tissues. The cyclophilin primer pair detected small variations in the amount of cDNA in each sample, and the...

E.C. Numbers:

Descriptors: ...chorea, multiple sclerosis, Parkinson disease, schizophrenia, Tourette disorder, neoplastic disorder prevention, diagnosis, gene therapy, recombinant vaccine DNA library DNA amplification tumor leuko virus retro virus lenti virus 4p16.3 chromosome-4 DNA sequence protein sequence (21, 45)

7/3,K/68 (Item 7 from file: 357) Links

Derwent Biotech Res.

(c) 2008 The Thomson Corp. All rights reserved.

0294137 DBA Accession No.: 2002-15984 PATENT

Novel human G-protein coupled receptor BMY7 (HGPRBM7) polypeptide, useful for modulators of HGPRBM7 activity that are useful for treating leukemia, cholecystitis, Grave's disease, epilepsy, dementia, depression vector-mediated recombinant protein gene transfer and expression in host cell for disease or

Untitled
disorder diagnosis, prognosis and gene therapy

Author: BATTAGLINO P; FEDER J N; MINTIER G; RAMANATHAN C S; WESTPHAL R; HAWKEN D R;
CACACE A; BARBER L; KORNACKER M G
Patent Assignee: BRISTOL-MYERS SQUIBB CO 2002
Patent Number: WO 200226823 Patent Date: 20020404 WPI Accession No.: 2002-435195
(200246)

Priority Application Number: US 315423 Application Date: 20010828
National Application Number: WO 2001US30351 Application Date: 20010926
Language: English

Abstract: ...a polynucleotide which represents the complementary sequence of (S1);
(vii) a polynucleotide corresponding to nucleotides 4-1218 or 1-1218 of (S1); or
(viii) a polynucleotide capable of hybridizing under stringent2) a
recombinant vector (III) comprising (II); (3) making a recombinant host cell
comprising (II); (4) a recombinant host cell (IV) produced using the above method;
(5) an isolated antibody (V... ..for diagnosing spinal cord- and brain-related
disorders and response to HGPRBMY7 therapy in humans; (4) diagnostic probes for
diseases and a patient's response to therapy; (5) diagnostic kits for...
...sequences that intervene between each of the predicted HGPRBMY7 transmembrane
domains; and (10) immunological or vaccine formulation comprising (I) or (II).
BIOTECHNOLOGY - Preparation: (I) is prepared by culturing (VI) under
conditions...each assay was determined by performing a parallel experiment using a
primer pair for the cyclophilin gene, which was expressed in equal amounts in all
tissues. The cyclophilin primer pair detected small variations in the amount of cDNA
in each sample, and these...
E.C. Numbers:

7/3,K/69 (Item 8 from file: 357) Links

Derwent Biotech Res.

(c) 2008 The Thomson Corp. All rights reserved.

0288501 DBA Accession No.: 2002-10348 PATENT

Polypeptide of ion channel family polypeptides, designated vanilrep4, useful as a
vaccine for inducing immune response against diseases such as neuropathies, algesia,
nerve injury, ischemia, stroke, incontinence, diabetes, obesity vector-mediated
recombinant protein gene transfer and expression in host cell, antibody, antagonist,
agonist, cDNA library and high throughput screening for disease and disorder
vaccine, diagnosis and therapy

Author: SMITH G; HAYES P D; SMART D; DAVIS J B; KELSELL R E
Patent Assignee: SMITHKLINE BEECHAM PLC 2002
Patent Number: EP 1170365 Patent Date: 20020109 WPI Accession No.: 2002-156636 (200221)

Priority Application Number: EP 2000202352 Application Date: 20000704

National Application Number: EP 2000202352 Application Date: 20000704

Language: English

Polypeptide of ion channel family polypeptides, designated vanilrep4, useful as a
vaccine for inducing immune response against diseases such as neuropathies, algesia,
nerve injury, ischemia, stroke, incontinencehost cell, antibody, antagonist,
agonist, cDNA library and high throughput screening for disease and disorder
vaccine, diagnosis and therapy

Abstract: ...host cell; (3) a recombinant host cell (IV) comprising (III) or their
membrane expressing (I); (4) preparation of (I) by culturing (IV); (5) an antibody
(Ab) immunospecific for (I); and (6... ..ACTIVITY - Analgesic; cerebroprotective;
antiinflammatory; antidiabetic; anorectic; vasotropic; uropathic. No biological data
given. MECHANISM OF ACTION - Vaccine; agonist and/or antagonist of (I). No
biological data given. USE - (I) and (II) are...reaction (PCR) and human cDNAs
prepared from various brain areas and peripheral tissues utilizing VR- 4 labeled
probe: 5'-ATGAGGACACGACCAACTGCA, VR-4 forward primer: 5'-GGAGGAAGGTGCTGAAGTCTC,
VR-4 reverse primer: 5'-CACTTACCCTCGTGCCGTGACAG. Signals obtained by Taqman PCR
were normalized to the housekeeping gene cyclophilin to correct for differences in
RNA integrity and quantity. Expression of VR-4 was highest into kidney and generally
higher in many peripheral tissues (e.g. liver, pancreas, placenta and prostate) than

Untitled
in central nervous system (CNS). Highest levels of VR-4 in CNS were observed in corpus callosum, hippocampus, spinal cord and pituitary gland.(29 pages)
E.C. Numbers:
Descriptors: ...neuralgia, algesia, nerve injury, neurodegeneration, ischemia, irritable bowel syndrome, stroke, inflammatory disorder, incontinence, diabetes, obesity vaccine, diagnosis, high throughput screening mammal tumor cancer DNA library hybridization DNA amplification analysis immunoassay DNA ...

7/3,K/70 (Item 1 from file: 149) Links
TGG Health&Wellness DB(SM)
(c) 2008 The Gale Group. All rights reserved.
03452758 Supplier Number: 170373862 (USE FORMAT 7 OR 9 FOR FULL TEXT)
A phytoestrogen-rich diet increases energy expenditure and decreases adiposity in mice.(Research)(Clinical report)

Cederroth, Christopher R.; Vinciguerra, Manlio; Kuhne, Francoise; Madani, Rime;
Doerge, Daniel R.; Visser, Theo J.; Foti, Michelangelo; Rohner-Jeanrenaud,
Francoise; Vassalli, Jean-Dominique; Nef Serge
Environmental Health Perspectives , 115 , 10 , 1467(7)

Oct ,
2007
Document Type: Clinical report Publication Format: Magazine/Journal
ISSN: 0091-6765
Language: English
Record Type: Fulltext Target Audience: Academic
word Count: 6013 Line Count: 00496

...rod, the mice were tested with the rod slowly accelerating at a constant pace from 4 to 40 rpm. The rotation speed was increased every 30 sec by 4 rpm, with a maximum test duration of 5 min. Mice were scored on their latency...

...each sample, and this quantity was normalized to the average of four endogenous control genes (cyclophilin B, (alpha) 2-tubulin, (beta)-tubulin, or (beta)-actin) as described by Vandesompele et al...

...weights were similar at weaning, a significant difference developed progressively in adults so that at 4 months of age, male HP mice weighed 7.6% less than LP mice (Figure 1B...

...phytoestrogens. Overall fat content was markedly lower in male HP mice (a 31% reduction at 4 months of age; Figure 1C), as determined by DEXAScan (Figure 1E). Interestingly, in females, reduction...

...At 20(degrees)C, HP and LP mice had similar body temperature (Figure 3C). To challenge the thermogenic capacity of these animals, we exposed them to cold at 4(degrees)C for a period of 4 hr. In the fed state, HP mice withstood the cold as well as the LP...

...0.05; data not shown) and down-regulating the lipogenic gene acetyl-CoA carboxylase-1 (4.2-fold decrease; n = 8-9/group; p < 0.05; data not shown), two important...

...isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J Nutr 131(4):1202-1206.

Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. 2000. Increased adipose...Handa RJ, Lund TD. 2004b. Behavioral effects of endocrine-disrupting substances: phytoestrogens. ILAR J 45(4):443-454.

Liang YQ, Akishita M, Kim S, Ako J, Hashimoto M, Iijima K, et...

Untitled

...Vinciguerra, (2) Francoise Kuhne, (1) Rime Madani, (1) Daniel R. Doerge, (3) Theo J. Visser, (4) Michelangelo Foti, (2) Francoise Rohner-Jeanrenaud, (2), (5) Jean-Dominique Vassalli, (1) and Serge Nef...

...Medicine, University of Geneva, Geneva, Switzerland; (3) National Center for Toxicological Research, Jefferson, Arkansas, USA; (4) Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands; (5) Department of Internal Medicine...

...and Development, Faculty of Medicine, University of Geneva, rue Michel Servet 1, CH-1211 Geneva 4, Switzerland. Telephone: 41 22 379 5193. Fax: 41 22 379 5260. E-mail: Serge.Nef...

7/3,K/71 (Item 2 from file: 149) Links

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

03173074 Supplier Number: 160532373 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers.(Research)

Thum, Thomas; Erpenbeck, Veit J.; Moeller, Julia; Hohlfeld, Jens M.; Krug, Norbert; Borlak, Jurgen

Environmental Health Perspectives , 114 , 11 , 1655(7)

Nov ,
2006

Publication Format: Magazine/Journal

ISSN: 0091-6765

Language: English

Record Type: Fulltext Target Audience: Academic

Word Count: 6172 Line Count: 00626

...for females, pregnancy was excluded before study participation. None of the subjects suffered acute bronchitis 4 weeks before bronchoscopy. Nonsmokers could not have smoked a cigarette for at least 5 years...

...calculated as the ratio of the gene of interest (numerator) versus an established housekeeping gene (cyclophilin A, denominator). We observed no significant differences in the gene expression results when experiments were...

...Sigma-Aldrich Chemie GmbH) were added, and cells were incubated at 37(degrees)C for 4 hr and centrifuged for 5 min (1,200 x g, 4 (degrees)C). The resulting supernatant was snap-frozen in liquid nitrogen and stored at -80...

...al. (1987). Samples (250 (micro)L) were treated with 250 (micro)L ammonium acetate (pH 4.5), and aliquots were treated with 100 u/mL (beta)-glucuronidase (Sigma-Aldrich Chemie GmbH...

...CYP1A1 gene expression (Willey et al. 1997).

CYP2A enzymes metabolize a variety of carcinogens including 4 -(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), which can lead to the development of lung...derived CD4+, CD8+, and (gamma)(delta) T cells in people with asthma after segmental allergen challenge. Am J Respir Cell Mol Biol 25:125-131.

London SJ, Idle JR, Daly AK...

...Smith GBJ, Bend JR, Bedard LL, Reid KR, Petsikas D, Massey T. 2003. Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes. Drug Metab Dispos...

Untitled

| | | | | |
|-------|---|-------|---|-------|
| ...30 | M | 98.1 | | |
| | | 22 | F | 113.2 |
| | | 30 | M | 95.4 |
| | | 29 | M | 89.2 |
| | | 27 | M | 108.2 |
| | | 26... | | |

...n = 10)

| | | | | | |
|-----------------|--|--------------|----|------------|-----|
| | | 36 | F | 13.5 | -- |
| | | 21 | F | 0 | -- |
| | | 24 | F | 0 | -- |
| | | 28 | M | 20.4 | -- |
| | | 24 | F | 2.3 | -- |
| | | 25 | F | 0 | -- |
| | | 26 | M | 0 | -- |
| | | 26 | F | 0 | -- |
| | | 23 | F | 0 | -- |
| Median (range) | | 24.5 (21-36) | -- | 0 (0-20.4) | -- |
| Smokers (n = 8) | | 28 | M | 194.8 | 87 |
| | | 30 | M | 175.8 | 137 |
| | | 22 | F | 400.0 | 157 |
| | | 30 | M | 241.4 | 88 |
| | | 29 | M | 156.8 | 93 |
| | | 27 | M | 310.0 | 136 |
| | | 26 | M | 369.0... | |

...6.7) 2 (1-3) 0.1 (0.1-0.2)
 Smokers (8) 8.1 (4.9-21.2)** 4
 (1-8)** 0.5 (0.1-1.4)**

| | | Lymphocytes Percent of cells | No. (x (10.sup.6)) | Eosinophils Percent of cells... |
|------------------|-----------|------------------------------------|-----------------------|---------------------------------------|
| Subjects (n) | | | | |
| ...0.3 (0.1-0.8) | 0 (0-1) | 0 (0-0.1) | | |
| Smokers (8) | 4.5 (3-5) | 0.4 (0.2-1.2) | 0 (0- | |
| 4) 0 (0-0.3) | | | | |

**p < 0.01 compared with nonsmokers.

Table 3. Oligonucleotide primers and...

...021130 Cyclophilin CTTGCCATTCTGGACCCAA

| Accession no. | Reverse primer (5'-3') | Product length (bp) |
|-------------------------|------------------------|------------------------|
| CYPs D01150 NM... | GATGGGTGACCCATAGCTT | 432 |

7/3,K/72 (Item 3 from file: 149) Links

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

02944507 Supplier Number: 106422250 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Key issues for the assessment of the allergenic potential of genetically modified foods: breakout group reports. (Genetically Modified Foods Mini-Monograph).

Germolec, Dori R.; Kimber, Ian; Goldman, Lynn; Selgrade, Mary Jane

Untitled

Environmental Health Perspectives , 111 , 8 , 1131(9)
June 15 ,
2003
Publication Format: Magazine/Journal
ISSN: 0091-6765
Language: English
Record Type: Fulltext Target Audience: Academic
Word Count: 10905 Line Count: 01001

...comparison of SPT/specific IgE results with the outcome of double-blind, placebo-controlled food challenge (DBPCFC), which is currently the "gold standard" for determining food allergy. Approximately 50% of positive ...

...an allergic reaction in previously sensitized individuals. Recently, the results of 10 independently conducted clinical challenge studies have been reported (Taylor et al. 2002). In these 10 well-defined clinical studies...

...involving a skewed response toward the production of IgE antibodies and Th2 cytokines (interleukin (IL)-4, IL-5, IL-6, IL-10, and IL-13). Models for safety assessment should show...

...the subjects also have clear clinical histories consistent with the specific allergy and if controlled challenge tests are positive. However, allergic responses after occupational exposure, which is ...made to identify appropriate individuals to provide serum. In addition, the use of postmarket surveillance challenge testing (e.g., DBPCFC) could be a valuable and safe part of the evaluation process...

...group agreed that the use of postmarket surveillance skin testing (for detection of sensitization) and challenge testing (e.g., DBPCFC for establishing reactivity) presents minimal safety concerns if done properly, and...

...the evidence that there are thresholds for sensitization and/or allergic reactions? Data from food-challenge studies in humans were provided for a number of the known allergenic foods (e.g. ...

...The current tools available to develop dose-response information include animal models and human food-challenge studies (Table 1). For both technical and ethical reasons, it would be very difficult to conduct human food-challenge or sensitization studies with novel proteins. Therefore, it was the opinion of the group that...

...dried whole egg.

(a) Data from Metcalfe et al. 1996. (b) Dose levels were 1, 4, or 16 g shrimp equivalents. NOEL was 4 g shrimp equivalents/207 g ice cream. No effects were elicited in this cohort with...

...Bernhisel-Broadbent J, Scanlon SM, Sampson HA. 1992. Fish hypersensitivity. I. In vitro and oral challenge results in fish-allergic patients. J Allergy Clin Immunol 89:730-737.

Bernhisel-Broadbent J...FM, Zeiger RS, Lehrer S, Sachs M, et al. 1988. Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure: a manual. J Allergy Clin Immunol 82:986-997. Burks...

...Jeanniton E, Hefle SL, Taylor, SL. 2001 Threshold dose for egg allergy determined by oral challenge (Abstract). J Allergy Clin Immunol

Untitled

107:760.

Daul CB, Morgan JE, Hughes J, Lehrer SB. 1988. Provocation-challenge studies in shrimp-sensitive individuals. J Allergy Clin Immunol 81:1180-1186.

Denepoux S, Eibensteiner...

...Pediatr Allergy Immunol 10:27-32.

Fujita C, Moriyama T, Ogawa T. 2001. Identification of cyclophilin as an IgE-binding protein from carrots. Int Arch Allergy Immunol 125:44-50.

Hansen...

...1999. Fish allergy: is cross-reactivity among fish species relevant?

Double-blind placebo-controlled food challenge studies of fish allergic adults. Ann Allergy Asthma Immunol 83:517-523.

Hillebrand JA, Thorne...

...allergy to very low doses of peanut protein: a randomized, double-blind, placebo-controlled food challenge study. J Allergy Clin Immunol 100:596-600.

Jones SM, Magnolfi CF, Cooke SK, Sampson...

...specificities. Approved Guideline, NCCLS document I/LA20-Avol. 17, No. 24 (ISBN 1-56238-343-4). Wayne, PA:NCCLS.

Roberts G, Golder N, Lack G. 2002. Bronchial challenges with aerosolized food...

...J, et al. 1999. Blocking antibodies induced by specific allergy vaccination prevent activation of CD(4.sup.+) T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 163:2944-2952...

...S86.

Dori R. Germolec, (1) Ian Kimber, (2) Lynn Goldman, (3) and Mary Jane Selgrade (4)

(1) Laboratory of Molecular Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, North...

...Cheshire, United Kingdom; (3) Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA; (4) National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. Environmental...

7/3,K/73 (Item 4 from file: 149) Links

TGG Health&wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

02942599 Supplier Number: 102677154 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Induction of NGF synthesis in astrocytes by onjisaponins of Polygala tenuifolia, constituents of kampo (Japanese herbal) medicine, Ninjin-Yoei-To.(nerve growth factor)

Yabe, T.; Tuchida, H.; Kiyohara, H.; Takeda, T.; Yamada, H.

Phytomedicine: International Journal of Phytotherapy & Phytopharmacology , 106(9) March , 2003

Publication Format: Magazine/Journal

ISSN: 0944-7113

Language: English

Record Type: Fulltext Target Audience: Academic

Word Count: 3895 Line Count: 00320

Untitled

...of the root of *Panax ginseng* Meyer (3 g), the root of *Angelica acutiloba* Kitagawa (4 g), the root of *Rehmannia glutinosa* Liboschitz var. *purpurea* Makino (4 g), the rhizome of *Atractylodes japonica* Koizumi ex Kitamura (4 g), the sclerotium of *Poria cocos* Wolf (4 g), the bark of the bark of *Cinnamomum cassia* Blume (2.5 g), the root...

...cm), and phenolic glycoside fraction and saponin fraction were obtained by eluting with EtOAc-MeOH (4:1) (1.5 l) and MeOH (2 l), respectively.

Preparation of onjisaponins
Onjisaponins were purified...

...GGCAAGTCAGCCTCT

| | |
|-------------------------|--------------------|
| ChAT (sense) | TCTTGTTAGCCTTCC-3' |
| | 5'-GGAGCCACCTGAGAT |
| | GTTCATGGAT-3' |
| ChAT (antisense) | 5'-CACAGACGAGGCTCT |
| | TTGGCAGCT-3' |
| cyclophilin (sense) | 5'-GGTCAACCCACCGT |
| | GTCTTCGA-3' |
| cyclophilin (antisense) | 5'-AACGGTTAGGTCGGT |
| | AAGTCAGAAC-3' |

Statistics

Statistical significance of difference of means was performed ANO...

...50 (microg/ml) for 24 h at 37 (degrees)C. As shown in Fig. 4, the induced NGF secretion was observed in NYT, *P. tenuifolia* extract (Pt) or *P. ginseng*...

...herbs of NYT, *P. ginseng* extract also induced NGF secretion from the cultured astrocytes (Fig. 4). It has been reported that *P. ginseng* extract increases the survival rate of nerve cells...

...Rb.sub.1) and (Rg.sub.1) have neurotrophic and neuroprotective actions against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- or (beta)-amyloid-induced neuronal cell death. (Rudakewich...

...therapeutic effects for the treatment of AD patients.

(FIGURE 2 OMITTED)

(FIGURE 3 OMITTED)

(FIGURE 4 OMITTED)

(FIGURE 6 OMITTED)

(FIGURE 7 OMITTED)

Acknowledgements

We thank Dr. Kazuo Toriizuka for helpful...

...of *Polygala tenuifolia* Willdenow, as effective adjuvants for nasal influenza and diphtheria-pertussis-tetanus vaccines. Vaccine 19: 4824-4834

Nitta A, Murakami Y, Furukawa Y, Kawatsura W, Hayashi K, Yamada K...
episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect 4: 79-95

Oderfeld-Nowak B, Bacia A, Gradkowska M, Fusco M, Vantini G, Leon A

...

...Untan-To) in the treatment of Alzheimer's disease: A pilot study.
Alzheimer's Reports 4:177-182

Wang Q, Iwasaki K, Suzuki T, Arai H, Ikarashi Y, Yabe T, Toriizuka...

...growth factor secretion by *Polygalae Radix*-extract containing active ingredients of Kami-untan-to. Phytomedicine 4: 199-205

Yabe T, Toriizuka K and Yamada H (1996) Kami-untan-to (KUT) improves

...

7/3,K/74 (Item 5 from file: 149) Links
 TGG Health&Wellness DB(SM)
 (c) 2008 The Gale Group. All rights reserved.
 02699955 Supplier Number: 126164113 (USE FORMAT 7 OR 9 FOR FULL TEXT)
 The 1.2-megabase genome sequence of Mimivirus.(Research Articles)(nucleocytoplasmic large DNA viruses)

Raoult, Didier; Audic, Stephane; Robert, Catherine; Abergel, Chantal; Renesto, Patricia; Ogata, Hiroyuki; La Scola, Bernard; Suzan, Marie; Claverie, Jean-Michel
 Science , 306 , 5700 , 1344(7)
 Nov 19 ,
 2004

Publication Format: Magazine/Journal

ISSN: 0036-8075

Language: English

Record Type: Fulltext; Abstract Target Audience: Academic

Word Count: 5975 Line Count: 00572

Author Abstract: ...synthesis enzymes, and one intein-containing gene. The size and complexity of the Mimivirus genome challenge the established frontier between viruses and parasitic cellular organisms. This new sequence data might help...

Text:

...been observed in the amino acid compositions of other DNA viruses rich in A+T (4). For any given amino acid, the relative usage of synonymous codons is also biased by...

...in isolated dsDNA viruses species such as bacteriophage T4 (8) and Bx21 (9), herpes virus 4 (10), and chlorella viruses (11). The chlorella viruses are also the first ones found to...

...NCLDVs. Finally, the Mimivirus genome encodes a putative peptidyl-prolyl cis-trans isomerase of the Cyclophilin family (ORF L605). This type of enzyme, seen here in a virus for the first...

...encodes (L136) a homolog to perosamine synthetase. Such an enzyme catalyzes the conversion of GDP-4-keto-6-deoxymannose to 4-N(H.sub.2)-4,6-dideoxymannose (perosamine), which is found in the O-antigen moiety of the lipopolysaccharide of...

...never yet reported in a virus, Mimivirus includes a NDK (Enzyme Classification (EC): 2.7.4.6) (ORF R418). NDK catalyzes the synthesis of nucleoside triphosphates (NTPs) other than ATP. This...

...Nanoarchaeum equitans (490 kb), Mycoplasma genitalium (580 kb), and Encephalitozoon cuniculi (2.498 kb) (Fig. 4). Despite its comparable genome size, Mimivirus exhibits fewer identified COGs. However, there was no specific...

...Virion resistance to adverse conditions. Mimivirus particles remained infectious during 1 year when kept at 4(degrees)C, 25(degrees)C, and 32(degrees)C in Page's amoeba saline (PAS...due to its unprecedented size. The numerous new genes related to the protein-translation apparatus challenge the established vision of viruses. Using these first viral representatives of universally conserved gene families...

...family)

L437 VV A32 virion packaging ATPase
 L396 VV A18 helicase
 L425 Capsid protein D13L (4 paralogs)
 R596 Thiol oxidoreductase (e.g., E10R)
 R350 VV D6R helicase, + 1paralog
 R400 S/T...

...Metabolism

| | | |
|---------------------|---|--------------------------|
| | domain | |
| R689 | N-acetylglucosamine-1-phosphate, uridyl-transferase | Polysaccharide synthesis |
| L136 | Sugar transaminase, dTDP-4 | |
| - ExoPolysaccharide | amino-4,6-dideoxyglucose biosynthesis | synthesis |
| L780 | dTDP-4 | |
| -dehydrorhamnose | ExoPolysaccharide reductase | synthesis |
| L612 | Mannose-6P isomerase | Glycosylation |
| L230 | Procollagen-lysine,2- | Glycosylation, capsid |
| ... | | |

...3.) N. Nandhagopal et al., Proc. Natl. Acad. Sci. U.S.A. 99, 14758 (2002).

(4.) C. L. Afonso et al., J. Virol, 73, 533 (1999).

(5.) L. H. Iyer, L...

...V. Koonin, J. Virol. 75, 11720 (2001).

(6.) R. L. Tatusov et al., BMC Bioinform 4, 41 (2003).

(7.) S. F. Altschul et al., Nucleic Acids Res. 25, 3389 (1997).

(8...)

7/3,K/75 (Item 6 from file: 149) Links

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

02382197 Supplier Number: 113820309 (USE FORMAT 7 OR 9 FOR FULL TEXT)

A method for normalizing microarrays using genes that are not differentially expressed.

Reilly, Cavan; Wang, Changchun; Rutherford, Mark
 Journal of the American Statistical Association , 98 , 464 , 868(11)
 Dec ,
 2003

Publication Format: Magazine/Journal; Refereed

ISSN: 0162-1459

Language: English

Record Type: Fulltext; Abstract Target Audience: Academic; Trade

Word Count: 9387 Line Count: 00781

...are only 41 nucleotide changes between VR2332 and its cell
 culture--passaged descendent Resp-PRRS vaccine strain, yet the
 Resp-PRRS vaccine strain has greatly reduced virulence in swine
 (Yuan, Mickelson, Murtaugh, and Faaberg 2001).

In our...

...genes, spotted cDNA microarrays were created to explore gene expression
 in PRRSV-infected PAMs at 4 and 24 hours postinfection. The arrays
 contained 139 ESTs (mostly identified through DDRT-PCR) spotted...

Untitled

...by one of three PRRSV strains of interest: VR2332, Neuro-PRRSV, or the Resp-PRRS vaccine strain. In addition, a common reference sample was created by "mock infecting" a set of...

...cDNA arrays is very similar (we give a detailed example of the latter in Sec. 4). We use $(x.sub.i)$ to denote the log (base 2)-transformed intensity for gene...

...each of the 2 samples there are 50 genes very differentially expressed $((\mu).sub.1) = (4, 1)$ and $((\mu).sub.2) = (0, -4)$ and 50 genes moderately differentially expressed $((\mu).sub.3) = (2, 1)$ and $((\mu).sub.4) = (0, -2)$, in addition to 1,000 genes with no difference in expression level $((\mu)...$

...span, and whereas recommendations have been given (e.g., Yang et al. (2002) "typically" used .4, whereas Dudoit et al. (2002) suggested values between .2 and .4), clearly the choice should depend on the number of genes in some complicated experiment-specific...

...such as patient age.

3. Reference sample structures, such as in the application in Section 4.

Our parametric modeling of the intensities is similar in spirit to the parametric modeling of...

...the data to indicate whether one of these control genes really is not a control.

4. APPLICATION TO CDNA ARRAYS WITH A COMMON REFERENCE SAMPLE
To illustrate the general model, we... $(\sigma).sub.2i.sup.2)$,
and
 $(y.sub.2ij)$ (approximately) $N((\phi).sub.4) + ((\eta).sub.i)$,
 $((\tau).sub.2i.sup.2)$,
where
(MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII...

...and this is not possible within the context of the analysis proposed by these authors.

4.1 Reference Sample Normalization

The usual application of global and control gene normalization is slightly...

...so that $((\phi).sub.1) = ((\phi).sub.2) + (\alpha)$ and $((\phi).sub.3) = ((\phi).sub.4) + (\alpha)$, then we can consistently estimate $((\phi).sub.3) - ((\phi).sub.1)$ with $(\bar{y}...$

$((\phi).sub.4) + ((\eta).sub.i)$,
 $((\tau).sub.2i.sup.2)) / (((\sigma).sub.1i.sup.2)((\sigma).sub...$

...one gene has an estimated log fold change with variance $6.96 \times (10.sup.-4)$ if we ignore the normalizing term; thus the ratio of the variances is 98.7. (The p value goes from $7.2 \times (10.sup.-4)$ to .064 if we use the $(t.sub.2)$ distribution for reference.) The median variance...

...we now just consider comparing a single Neuro-PRRSV array to a single Resp-PRRS vaccine array (the comparison in the middle of the top row of Fig. 2 and Fig...

...discrepancy is clear--a central 95% credible interval for the fold change of GAPDH is (.4, .9, 1.7). Thus, although this gene is most likely not differentially expressed (as we...

Untitled
...if we normalize using this gene, then all fold changes will be too high.
Figure 4 displays credible intervals for the log fold changes.
In this figure, the lower x-axis...

...if there were no interaction between the dye effect and array, as discussed in Section 4, then we would expect $((\phi)_{sub.2}) - ((\phi)_{sub.1}) - (((\phi)_{sub.4}) - ((\phi)_{sub.3}))$ to be centered at 0. In fact, a central 95% credible interval...

...to the reference sample normalization method are almost surely not satisfied for this comparison.

(FIGURE 4 OMITTED)

(FIGURE 5 OMITTED)

6.3 Results Based on All Arrays

We can easily extend...

...sub.1i)), $((\sigma)_{sub.i.sup.2}))$,
and
 $((y)_{sub.2ij})$ (approximately) $N(((\phi)_{sub.4}) + ((\eta)_{sub.i}),$
 $((\tau)_{sub.i.sup.2}))$,
where
(MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII...

...efficient estimates. In addition, we suppose that four genes commonly used as housekeeping genes (GAPDH, cyclophilin, (beta)-actin, and HPRT) are control genes with prior probability .95. An examination of the ...

...interval for the fold change in expression for VR2332 relative to Neuro-PRRSV is (1.4, 4.82). This gene is known to be induced by interferon-(alpha) (IFN-(alpha)) and some...

...is provided by the gene GRP78 (accession number AW231967), with credible intervals of (1.24, 4.26) for VR2332 relative to Neuro-PRRSV and (1.93, 6.26) for VR2332 relative to the Resp-PRRS vaccine strain. It is known that GRP78 plays a role in the conformational maturation of some ...

...A Robust Composite Method Addressing Single and Multiple Slide Systematic Variation," Nucleic Acids Research, 30(4) 1-10.

Yang, Y. Dudoit, S., Luu, P., and Speed, T. (2001), "Normalization for cDNA...

7/3,K/76 (Item 7 from file: 149) Links

TGG Health&wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

01919760

Supplier Number: 63566596 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Sirolimus and ciclosporin for renal transplantation.(Commentary)(Brief Article)(Statistical Data Included)

Halloran, Philip F

The Lancet , 356 , 9225 , 179

July 15 ,

2000

Document Type: Brief Article; Statistical Data Included Publication Format:
Magazine/Journal; Refereed

ISSN: 0099-5355

Language: English

Record Type: Fulltext Target Audience: Professional

Word Count: 1111 Line Count: 00096

Untitled

...immunophilin-binding drugs. These drugs form complexes with abundant intracellular proteins called immunophilins: ciclosporin with cyclophilin (CP), and tacrolimus and rapamycin with the tacrolimus-binding protein (FKBP). The ciclosporin-CP and...

...regulators. The rapamycin-FKBP complex binds to a kinase called the target of rapamycin (TOR).(4) TOR is central to a pathway by which receptors for growth factors control the cell...

...tacrolimus, mycophenolate mofetil, the anti-CD25 monoclonals basiliximab and daclizumab, and now rapamycin. The main challenge of the next decade is learning how to capture the potential of these new agents...

...new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28: 727-32.

(4) Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin...

7/3,K/77 (Item 8 from file: 149) Links

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

01432140 Supplier Number: 14784551 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Multifactorial nature of human immunodeficiency virus disease: implications for therapy.

Fauci, Anthony

Science , v262 , n5136 , p1011(8)

Nov 12 ,

1993

Publication Format: Magazine/Journal

ISSN: 0036-8075

Language: English

Record Type: Fulltext; Abstract Target Audience: Academic

Word Count: 9061 Line Count: 00708

...heavy viremia is responsible for the seeding of virus to various organs, including the brain[4] and lymphoid tissues. There is a dramatic perturbation in the numbers of peripheral blood mononuclear...activation. It has been demonstrated in vitro that CSA interferes with the binding of cellular cyclophilin A and B to HIV gag protein and in this manner might interfere with HIV...IL-2 and IFN-[gamma] and a predominance of TH-2 responses mediated by IL-4, IL-5, IL-6, and IL-10[71]. The potential exists for correcting this imbalance...

...receptors. Other approaches at intermittent stimulation of the immune system with materials such as polio vaccine[81], typhoid vaccine[82], and dinitrochlorobenzene (DNCB)[83] have yielded variable results. Finally, the use of killed HIV or its protein components as a therapeutic vaccine is currently in clinical trials, and there have been reports suggesting beneficial effects on [CD4...however, since these multifactorial components of HIV pathogenesis occur in phases that may overlap (Fig. 4). Certain types of interventions may be appropriate at one stage of disease and contraindicated at...

...Conference on AIDS, Berlin, 6 to 11 June 1993, abstract WS-A15-1, p. 31. [4.] R. W. Price et al., Science 239, 586 (1988); R. Geleziunas, H. M. Schipper, M...

Untitled

...and H. W. Shephard, J. AIDS 3, 177 (1990); H. W. Sheppard et al., *ibid.* 4, 704 (1991); H. Z. Bass et al., *Clin. Immunol. Immunopathol.* 64, 63 (1992); Z. F...et al., *Eur. J. Immunol.* 21, 2883 (1991); R. Bertini et al., *Eur. Cytokine New.* 4, 39 (1993); K. M. Mohler et al., *J. Immunol.* 151, 1548 (1993); J. Agosti, unpublished...Lane, AIDS 3, S181 (1989); D. H. Schwartz, G. Skowron, T. C. Merigan, *J. AIDS* 4, 11 (1991); A. G. Clark, M. Holodniy, D. H. Schwartz, D. A. Katzenstein, T. C ...

7/3,K/78 (Item 9 from file: 149) Links

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

01428741 Supplier Number: 14515511 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Structure-based design of a cyclophilin-calcineurin bridging ligand.

Alberg, David G.; Schreiber, Stuart L.

Science , v262 , n5131 , p248(3)

Oct 8 ,

1993

Publication Format: Magazine/Journal

ISSN: 0036-8075

Language: English

Record Type: Fulltext; Abstract Target Audience: Academic

Word Count: 2136 Line Count: 00172

Structure-based design of a cyclophilin-calcineurin bridging ligand.

Author Abstract: ...the immunosuppressant cyclosporin A (CsA), which inhibits the proliferation of T lymphocytes by forming a cyclophilin -CsA-calcineurin complex, was designed with the known three-dimensional structure of a cyclophilin-CsA complex. The conformational restraints in TCsA appear to be responsible for its greater affinity for cyclophilin and calcineurin relative to CsA.

Text:

It has been noted that the conformations of CsA and FK506, when bound to cyclophilin A and FK506-binding protein 12 (FKBP12), respectively, differ markedly from their unbound conformations in the solid state and in solution[3,4]. Although the conformations adopted by these ligands while they are simultaneously bound to their immunophilin...

...is capped by a type II' [beta] turn at [Sar.sup.3] and [MeLeu.sup.4]. When CsA is bound to cyclophilin A (Fig. 1)[12,13], the backbone of CsA is turned inside-out; the intramolecular...

...are absent. In light of these findings, it is evident why early efforts to prepare cyclophilin A ligands on the basis of the unbound conformation of CsA met with little success...

...interfere with binding, we chose to alter a segment that is not in contact with cyclophilin[17-19] and that can be modified without significant loss of immunosuppressive activity[20, 21...

...2 shows the local structure of CsA residues 6 to 9 in their free and cyclophilin A-bound conformations. The relative orientations of the C[alpha]-N and C[alpha]-C...

...the oxazolidinone 2[26], which is derived from L-glutamic acid, was converted to aldehyde 4[27]. Condensation of this aldehyde with

Untitled
D-cysteine methyl ester provided the desired heterocycle 7...

...9], and it suggest that TCsA and CsA have different conformational properties.

We compared the cyclophilin A binding affinity of TCsA to that of CsA by determining each compound's ability to inhibit the rotamase activity of cyclophilin A[29]. The affinity of TCsA [inhibition constant ([K.sub.i]) = 2 [+ or -] 0.5 nM] for cyclophilin A is three times that of CsA for cyclophilin A ([K.sub.i] = 6 [+ or -] 0.5 nM)[30, 31]. Because the L-[Ala.sup.7]-D-[Ala.sup.8] fragment of CsA makes no direct contact with cyclophilin A, it is reasonable to expect that the bicyclic fragment of TCsA also does not...

...the L-[Ala.sup.7]-D-[Ala.sup.8] region of (of CsA) of the cyclophilin A-CsA complex does not contact calcineurin, the binding data suggest that this speculation has merit. The affinity of cyclophilin A-TCsA for calcineurin [[K.sub.i] = 78 [+ or -] 14 nM; inhibition of phosphatase activity[32]] is approximately two to three times that of cyclophilin A-CsA for calcineurin ([K.sub.i] = 198 [+ or -] 16 nM)[33]. In addition, TCsA...50% inhibition concentration ([IC.sub.50]) for TCsA = 2 nM; [IC.sub.50] for CsA = 4 nM[34, 35]. [NFAT activity appears to be dependent on the calcineurin-mediated dephosphorylation of...

...The collective inhibitory data from biochemical and cellular assays reveal a systematic enhancement in the cyclophilin A- and calcineurin-binding properties of TCsA relative to those of CsA. The enhancement is...

...complexity of receptor-ligand interactions in the solution phase. For example, it is a significant challenge to correctly anticipate the differential effect of the molecule restraint in TCsA on the entropy...

...L. Schreiber, Cell 70, 365 (1992). [3.] K. wuthrich et al., Science 254, 953 (1991). [4.] W. L. Jorgensen, ibid., p. 954. [5.] L. D. Zydowsky et al., Protein Sci. 1...

...Nat'l. Acad. Sci. U.S.A. 87, 9231 (1990)]. [31.] The binding of TCsA to cyclophilin A is better than that of all of the roughly 100 CsA analogs reported, with the exception of [(Boc)Dab][CsA.sup.-8] ([K.sub.i] = 2.4 nM), whose reported affinity for cyclophilin is comparable to that of TCsA [J. L. Kofron, P. Kuzmic, V. Kishore, E. Colon ...

...Fiering, J. P. Northrop, G. P. Nolan, G. R. Crabtree, L. A. Herzenberg, Genes Dev. 4, 1823 (1990). [35.] Inhibitory constants were calculated from data obtained at seven different concentrations (four...

Special Features:
Descriptors: Cyclophilin--
Geographic Codes:

7/3,K/79 (Item 10 from file: 149) Links
TGG Health&Wellness DB(SM)
(c) 2008 The Gale Group. All rights reserved.
01245382 Supplier Number: 09184407 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Current status of renal transplantation.

Suranyi, Michael G.; Hall, Bruce M.
The Western Journal of Medicine, v152, n6, p687(10)
June,

Untitled

1990

Publication Format: Magazine/Journal

ISSN: 0093-0415

Language: English

Record Type: Fulltext; Abstract Target Audience: Professional

word Count: 11855 Line Count: 01069

...there have been parallel improvements in the detailed understanding of the fundamental processes causing rejection.[4,5] In clinical transplantation, improvements have been made in tissue typing, immunosuppression, and patient care...practical but may add difficulty to transplant matching.[216-218] Efforts to develop an effective vaccine against CMV have been mostly disappointing,[219-221] but passive immunization with CMV hyperimmune globulin...comparing triple-drug and double-drug therapy in renal transplantation. Transplantation 1988; 45:913-918

4. Krensky AM, Suranyi MG, Clayberger C. et al: Advances in the immunobiology and clinical practice...Kidney Int 1987; 32:19-25

189. Handschumacher RE, Harding MW, Rice J, et al: Cyclophilin : A specific cytosolic binding protein for cyclosporin A. Science 1984; 226:544-547

190. Lewis...

...J Infect Dis 1988; 20:135-139

219. Balfour HH, Welo PK, Sachs GW: Cytomegalovirus vaccine trial in 400 renal transplant candidates. Transplant Proc 1985; 17:81-83

220. Farrar GH, Bull JR, Greenaway PJ: Prospects for the clinical management of human cytomegalovirus infections. Vaccine 1986; 4:217-224

221. Brayman KL, Dafoe DC, Smythe WR. et al: Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine-Interim results of a randomized trial. Arch Surg 1988; 123:1502-1508

222. Sydman DR...RL, Shaw BW, et al: The acquired immunodeficiency syndrome and transplantation. Transplantation 1987; 44:1-4

236. Dummer JS, Erb S, Breinig MK, et al: Infection with human immunodeficiency virus in...

7/3,K/80 (Item 1 from file: 444) Links

New England Journal of Med.

(C) 2008 Mass. Med. Soc. All rights reserved.

00129031

Copyright 2007 by the Massachusetts Medical Society

Case 12-2007: A 56-Year-Old Woman with Renal Failure after Heart-Lung Transplantation (Case Records of the Massachusetts General Hospital)

Goes, Nelson B.; Colvin, Robert B.

The New England Journal of Medicine

Apr 19, 2007 ; 356 (16),pp 1657-1665

Line Count: 00370 word Count: 05110

Text:

...nifedipine, thyroxine, calcitriol, trimethoprim, oral clotrimazole, folic acid, calcium carbonate, multivitamins, and vitamin A; pneumococcal vaccine had been administered after her splenectomy... ..pressure was 130/80 mm Hg, the pulse 90 beats per minute, the temperature 36.4 degreesC, and the oxygen saturation 99% when the patient was breathing ambient air. There was... ..mild disease, and stage 5

Untitled

kidney failure. According to this classification, the patient has stage 4 disease, a stage at which dialysis is likely to be required within a year and...renal replacement therapy. Chronic kidney disease increases the risk of death by a factor of 4 among recipients of nonrenal solid-organ transplants. Several factors are associated with chronic kidney disease...immunosuppressed patients. Although BK-virus nephropathy is almost exclusively found among renal transplant recipients, (Ref. 4) there are reported cases in recipients of heart, lung, and kidney-pancreas allografts. (Ref. 5... ..of lungs, heart, pancreas, and liver possible. These products cross the cytoplasmic membrane; cyclosporine binds cyclophilin and tacrolimus binds FKBP2, forming complexes that prevent calcineurin from dephosphorylating the nuclear factor of... ..profile improved, and 6 years after the renal transplantation, the cardiac risk ratio was 2.4 (desirable ratio, less than 5) and the serum creatinine level was within the normal range...

Cited References

...C. Predicting progression in membranous glomerulonephritis. *Nephrol Dial Transplant* 1992;7:Suppl 1:48-52.
4. Mylonakis E, Goes N, Rubin RH, Cosimi AB, Colvin RB, Fishman JA. BK virus in...

7/3,K/81 (Item 2 from file: 444) Links

New England Journal of Med.

(c) 2008 Mass. Med. Soc. All rights reserved.

00125853

Copyright 2004 by the Massachusetts Medical Society

Drug Therapy: Immunosuppressive Drugs for Kidney Transplantation (Review Article)

Halloran, Philip F.

The New England Journal of Medicine

Dec 23 , 2004 ; 351 (26),pp 2715-2729

Line Count: 00622

Word Count: 08587

Text:

...between lymphoid tissues, regulated by chemokine and sphingosine-1-phosphate (S-1-P) receptors. (Ref. 4) APCs present donor antigen to naive and central memory T cells. Some presentation of antigen... ..receptor α chain (CD25), and interleukin-2. Receptors for a number of cytokines (interleukin-2, 4, 7, 15, and 21) share the common γ chain, which binds Janus kinase 3 (JAK3... ..cornerstone of immunosuppression in transplantation for two decades, is in effect a prodrug that engages cyclophilin, an intracellular protein of the immunophilin family, forming a complex that then engages calcineurin. (Ref... ..effects. (Ref. 89-92)

LEA29Y

LEA29Y is a second-generation cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) immune globulin that is a fusion protein combining CTLA-4 (which engages CD80 and CD86) with the Fc portion of IgG. Results of a phase... ..the cytokine receptor (gamma) chain, participates in the signaling of many cytokine receptors (interleukin-2, 4, 7, 9, 15, and 21) (Figure 1). JAK3 inhibitor CP-690,550 (Ref. 39) was... ..reduced reliance on glucocorticoids (Ref. 94) and calcineurin inhibitors. Some examples are listed in Table 4. Developing evidence-based approaches to this confusing choice of protocols presents a challenge.*Table 4.-Examples of Current and Experimental Immunosuppressive Drug Protocols (Ref. 95-99) *...TABLE OMITTED...

Cited References

...migration: two sides of the same coin. *N Engl J Med* 2000;343:1020-34.
4. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1... ..in mice do not require perforin or granzymes A and B. *Am J Transplant* 2004;4:705-12.
15. Robertson H, Ali S, McDonnell BJ, Burt AD, Kirby JA. Chronic renal... ..B. Lymphomas after solid organ transplantation: a Collaborative Transplant Study

Untitled

- report. Am J Transplant 2004;4:222-30.
26. Nicleleit V, Klimkait T, Binet IF, et al. Testing for polyomavirus type...
...activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation 1995;59:1400-4.
30. Elion GB. The George Hitchings and Gertrude Elion Lecture: the pharmacology of azathioprine. Ann... ..Improved long-term graft survival as compared with Sandimmune. Am J Transplant 2002;2:100-4.
50. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in... ..contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997;175:901-4.
60. Gabardi S, Tran JL, Clarkson MR. Enteric-coated mycophenolate sodium. Ann Pharmacother 2003;37... ..Neumayer HH. Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 2004;4:130-1.
63. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention... ..in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004;4:1019-25.
76. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of... ..JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004;4:996-1001.
89. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade... ..donation and transplantation trends in the United States, 2001. Am J Transplant 2003;3:Suppl 4:7-12.
102. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP... ..marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4:378-83.
104. U.S. Renal Data System. USRDS 2003 annual data report: atlas of... ..Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004;4:Suppl 7:13-53.
110. Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and... ..DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4:905-13.
112. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 2004;4 :384-9.
113. Matas AJ. What's new and what's hot in transplantation: clinical... ..Reports of large immunosuppression trials in kidney transplantation: room for improvement. Am J Transplant 2004;4:738-43.
115. Hariharan S, McBride MA, Cohen EP. Evolution of endpoints for renal transplant... ..Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004;4:561-8.
118. Fredericks S, Holt DW, MacPhee IA. The pharmacogenetics of immunosuppression for organ... ..From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. Am J Transplant 2004;4:299-310.
120. MacPhee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated... ..on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004;4:914-9.
122. Auchincloss H Jr. In search of the elusive holy grail: the mechanisms...

7/3,K/82 (Item 3 from file: 444) Links
New England Journal of Med.
(c) 2008 Mass. Med. Soc. All rights reserved.
00110975
Copyright 1993 by the Massachusetts Medical Society

Seminars in Medicine of the Beth Israel Hospital, Boston: New Concepts About The Mast Cell (Review Articles)

Galli, Stephen J.
The New England Journal of Medicine
Jan 28 , 1993 ; 328 (4),pp 257-265
Line Count: 00563 word Count: 07778
Page 70

Untitled

Text:

...the receptor (FcεRI) that binds with high affinity the Fc portion of IgE antibody (Ref. 4). When IgE antibodies bound to the cells' receptors recognize specific multivalent antigen, mast cells and...chronic inflammatory or immunologic responses. For example, the wheal-and-flare response to intradermal allergen challenge, or the bronchoconstriction observed in sensitive subjects immediately after aerosol allergen challenge, clearly reflects the acute effects of mast-cell-derived mediators (Ref. 7,8,22). In... mast cells is followed by the recurrence or development of symptoms hours after the initial challenge (Ref. 8,23). These late-phase reactions are associated with enhanced vascular permeability and leukocytic infiltration at sites of allergen challenge (Ref. 8,23). Indeed, much of the morbidity associated with allergic asthma and other allergic... secrete product (or both) for multifunctional pro-inflammatory or mitogenic cytokines, including interleukin-1, 3, 4, 5, and 6; granulocyte-macrophage colony-stimulating factor; interferon gamma; four members of the C...sub 30-40)-human serum albumin DNP(sub 30-40)-HSA) intravenously. Six hours after challenge with DNP(sub 30-40)-HSA, the mice were killed and the numbers of mast...indicate that basophils can also be a potential source of cytokines -- in this case, interleukin- 4 (Ref. 10...mast cells contributes to the small-intestinal ion secretion induced during intestinal anaphylaxis to allergen challenge or in response to electrical stimulation of intestinal nerves, and that histamine and serotonin, which...

Cited References

- ...Valent P, Bettelheim P. The human basophil. Crit Rev Oncol Hematol 1990;10:327-52.
4. Kinet J-P. The high-affinity receptor for IgE. Curr Opin Immunol 1989;2:499...
...bone marrow cell populations that express high-affinity Fc(sub e) receptors and produce interleukin 4 are highly enriched in basophils. Proc Natl Acad Sci U S A 1991;88:2835...endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci U S A 1991;88:4220-4.
51. Leung DYM, Pober JS, Cotran RS. Expression of endothelial-leukocyte adhesion molecule-1 in...et al. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol 1990;144:3891-7.
71. Kita H, Ohnishi T, Okubo Y, Weiler D...

7/3,K/83 (Item 4 from file: 444) Links
New England Journal of Med.
(c) 2008 Mass. Med. Soc. All rights reserved.
00107022
Copyright 1990 by the Massachusetts Medical Society

T-Lymphocyte-Antigen Interactions In Transplant Rejection (Mechanisms of Disease)

Krensky, Alan M.; Weiss, Arthur; Crabtree, Gerald; Davis, Mark M.; Parham, Peter.
The New England Journal of Medicine
Feb 22, 1990 ; 322 (8),pp 510-517
Line Count: 00628 word Count: 08667

Text:

...recurrence of disease, and psychosocial problems. Identifying more specific modes of immunosuppression therefore remains a challenge for clinical medicine...T-lymphocyte recognition required both foreign antigen and the body's own MHC molecule (Ref. 4). A current view of this phenomenon of MHC restriction is that the antigen receptor of... initiated by the binding of antigen to the T-cell receptor are best understood (Fig. 4). *Figure 4.-Schematic Representation of the Cytoplasmic and Nuclear Events Involved in T-Cell Activation. Ligands (open... ...to phospholipase C (PLC) by a guanine-nucleotide-binding protein (G). Activated PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP(sub 2)), yielding inositol 1,4,5-triphosphate (IP(sub 3)) and diacylglycerol (DG). IP(sub 3) mobilizes calcium
Page 71

Untitled

ions from...second wave of genes (such as the interleukin-2 gene). PI denotes phosphatidylinositol, PIP phosphatidylinositol 4-phosphate, PA phosphatidic acid, IP(sub 2) inositol 1,4-phosphate, and IP(sub 1) inositol 4-phosphate *. **FIGURE OMITTED...to this pathway activate an intracellular phospholipase C that cleaves the phosphodiester linkage in phosphatidylinositol 4,5-bisphosphate. This hydrolysis results in the production of two potent second messengers, inositol 1,4,5-triphosphate and diacylglycerol, which in turn can induce calcium mobilization and the activation of...level of cytoplasmic free calcium is thought to result from the action of inositol 1,4,5-triphosphate on a specific receptor within the endoplasmic reticulum that releases calcium ions from...a calcium channel that is not voltage-gated and that is responsive to inositol 1,4,5-triphosphate (Ref. 22). The sustained rise in the level of cytoplasmic free calcium appears...The other second messenger derived from the hydrolysis of phosphatidylinositol 4,5-bisphosphate is diacylglycerol. Like phorbol esters, it activates a family of homologous calcium- and...not been identified. This may be due partly to the difficulties in studying the phosphatidylinositol 4,5-bisphosphate pathway in vitro and to the complexity of phospholipase C. At least four...II on inducible cells and triggering macrophage function, B-cell growth and differentiation factors interleukin-4, interleukin-5, and interleukin-6 induce the clonal expansion of B cells that have been...production has occurred, the T cells divide under the influence of interleukin-2 and interleukin-4 and begin to assume different functions, such as cytotoxicity. The genes for serine esterases, thought...our understanding of the events between the immediate biochemical changes due to receptor occupancy (Fig. 4) and the consequent biologic effects exists for most, if not all, membrane receptors. For this...controversy about the roles of calcium mobilization, protein kinase C activation, and tyrosine kinases (Fig. 4). One consequence of the occupancy of the receptor by antigen that is closely related to...transcription-control regions of several early-activation genes, such as that for interleukin-2 (Fig. 4). Short fragments of DNA containing only 10 to 20 base pairs can activate transcription in...in the regulation of the early T-cell-activation genes. Furthermore, the cyclosporine-binding protein, cyclophilin, is identical to peptidylprolyl cis-trans isomerase, which is required for the proper folding of many proteins (Ref. 40). Therefore, the binding of cyclosporine to cyclophilin probably inhibits the folding of protein and by this means interferes with the transmission of...membrane to induce the expression of new gene products and functions is progressing rapidly. The challenge for the future will be to apply these experimental systems to clinical transplantation...

Cited References

1. Mason DW, Morris PJ. Effector mechanisms in allograft rejection. *Annu Rev Immunol* 1986; 4:119-45.
2. Dinarello CA, Mier JW. Lymphokines. *N Engl J Med* 1987; 317:940...In: Paul WE, ed. *Fundamental Immunology*. 2nd ed. New York: Raven Press, 1989:489-539.
4. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis...1984; 312:315-21.
22. Kuno M, Gardner P. Ion channels activated by inositol 1,4,5-trisphosphate in plasma membrane of human T-lymphocytes. *Nature* 1987; 326:301-4.
23. Cantrell DA, Davis AA, Crumpton MJ. Activators of protein kinase C down-regulate and...cell CD3-zeta,eta heterodimer expression and coupling to phosphoinositide hydrolysis. *Science* 1988; 242:571-4.
31. Crabtree GR. Contingent genetic regulatory events in T lymphocyte activation. *Science* 1989; 243:355 cyclophilin. *Nature* 1989; 337:473-5. □